Funding Organization
National Cancer Institute
1000 opportunities
About
No description available for this funder.
Grants (1000)
Regulatory Mechanisms of APOBEC3B Mutagenic Activity in Cancer
openOct 31, 2029$40,367 - $40,367
Rewire-CAN-Therapeutic Rewiring of Colorectal Cancer
openApr 30, 2027$182,639 - $182,639
Advancing Renal Mass Diagnosis and Management through AI-Enhanced Decision Support Systems (RMM-DSS)
openMay 31, 2031$632,670 - $632,670
Characterization of Germline and Somatic Genetic Variants in Langerhans Cell Histiocytosis Pathogenesis
openMay 31, 2028$321,000 - $321,000
Lung cancer subtype risk stratification: Validation in real world cohorts
openMay 31, 2031$714,192 - $714,192
Clonal hematopoiesis as a targetable mechanism of resistance to therapy in thyroid cancer.
openMay 31, 2031$752,808 - $752,808
2026 Mammary Gland Biology Gordon Research Conference and Seminar
openApr 30, 2027$10,000 - $10,000
Second-generation new-chemical-entity nanomedicine to target treatment resistance in pancreatic cancer
openMay 31, 2031$667,482 - $667,482
Effect of Bundling Home-Based Self-Collection for Cervical and Colorectal Cancer Screening: The My Body, My Test-4 Trial
openMay 31, 2031$645,317 - $645,317
Targeting Epigenetic Vulnerabilities in Osteosarcoma to Enhanced Immunotherapy
openMay 31, 2028$426,828 - $426,828
Expanding the xenotopic toolbox for compartment-specific manipulation of redox stress in cancer
openMay 31, 2028$480,205 - $480,205
The molecular mechanisms underlying PHF6-mutation-mediated hematologic malignancies
openMay 31, 2031$544,988 - $544,988
Develop a human pluripotent stem cell-derived preclinical model for NUT Carcinoma
openMay 31, 2028$157,000 - $157,000
Microfluidic Isolation and Deep Learning-based Profiling of Subtypes of Circulating Tumor Cells during Epithelial Mesenchymal Transition
openMay 31, 2029$607,488 - $607,488
Targeting YBX1 to enhance radiation sensitivity in very high risk medulloblastoma
openMay 31, 2028$482,624 - $482,624
Role of tumor biomechanics on drug-receptor engagement
openMay 31, 2031$648,579 - $648,579
Leveraging Social Media Influencers to Improve Anal Cancer Prevention
openMay 31, 2028$407,543 - $407,543
Investigating the role of ZBTB7A in AML differentiation
openMay 31, 2031$543,984 - $543,984
Ultrasensitive sequencing to detect local and circulating tumor burden as a driver of recurrence in patients with resectable pancreas cancer
openMay 31, 2027$120,403 - $120,403
Transcriptional and post-transcriptional drivers of Melanoma
openMay 31, 2031$534,325 - $534,325
Investigating the bidirectional tumor-host crosstalk in cachexia and pancreatic ductal adenocarcinoma
openMay 31, 2028$142,251 - $142,251
Chrono-Cuisine: Investigating Meal Timing Patterns and Cancer Susceptibility
openMay 31, 2028$395,973 - $395,973
Investigating the Role of AR Extrachromosomal DNA (ecDNA) in Bipolar Androgen Therapy for Advanced Prostate Cancer
openMay 31, 2030$44,819 - $44,819
Spatial and Temporal control of gene therapy in CAR-T cells with ionizing radiation to improve local and distant control of solid tumors
openMay 31, 2031$651,674 - $651,674
Addressing Unmeasured Covariates in Source Cohorts with Transfer Learning for Survival Outcomes
openMay 31, 2028$421,685 - $421,685
An Antibody-Drug Conjugate Targeting CCRL2 to Improve Outcomes in High-risk MDS and MDS-related AML
openMay 31, 2028$155,479 - $155,479
Computational Approaches to Reconstruct the Evolutionary History of Cancer Metastases
openMay 31, 2031$688,073 - $688,073
Elucidate the mechanism of targeting MTR to enhance anti-tumor immunity in KRAS-driven lung cancer
openMay 31, 2031$516,808 - $516,808
The Role of Estrogen Receptor in Regulating Breast Cancer Cell Invasion
openMay 31, 2031$544,929 - $544,929
Understanding the Implications of EP300 deficiency in Adult T-Cell Leukemia/Lymphoma
openMay 31, 2031$672,960 - $672,960
Establishing the role of hypomorphic BRCA1 and BRCA2 variants in cancer risk, etiology and response to therapy
openMay 31, 2031$741,738 - $741,738
Reframing BRCA1 Function: A Coordinator of Lagging Strand Synthesis
openMay 31, 2031$469,628 - $469,628
One-ended Break Repair in Mammalian Cells
openMay 31, 2031$524,110 - $524,110
Molecular Imaging of the Immune-Suppressive TME in Prostate Cancer
openMay 31, 2031$477,674 - $477,674
Cyclic Peptides as Adaptors for Universal CARs
openMay 31, 2028$379,644 - $379,644
Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategies
openMay 31, 2031$658,033 - $658,033
Radiation-induced fate shift of neural progenitors toward endothelial-like cells in human cortical organoids
openMay 31, 2028$368,156 - $368,156
THE INTEGRATED STRESS RESPONSE IN GBM PATHOGENESIS AND RESPONSE TO THERAPY
openMay 30, 2031$659,201 - $659,201
Cancer cells with hybrid epithelial and mesenchymal phenotypes for deformability-based classification
openMay 31, 2028$161,500 - $161,500
Controlling tumor-infiltrating regulatory T cell function by the IL-17-Ybx1 signaling pathway
openMay 31, 2031$484,918 - $484,918
The role of ERBB signaling in ibrutinib-resistant mantle cell lymphoma
openMay 31, 2028$457,683 - $457,683
Growth in Medicare Advantage Enrollment and its Implications for Cancer Care Quality
openMay 31, 2028$83,811 - $83,811
Elucidating the impacts of body composition and physical activity on anti-tumor immunity and cancer control in advanced stage high-grade serous carcinoma
openMay 31, 2031$713,312 - $713,312
Physical and Functional Improvement via Cancer Rehabilitation Triaging (PIVOT) Trial
openMay 31, 2031$544,080 - $544,080
Blood-based early detection of viral precancers
openMay 31, 2031$642,406 - $642,406
Creating cancer-specific genotoxicity by targeting Cas9 nickase to focal gene amplifications
openMay 31, 2031$622,611 - $622,611
Defining determinants of the lineage identity program in lung cancer and therapeutic resistance
openMay 31, 2031$631,487 - $631,487
Targeting the Golgi Secretory Pathway in Chromosome 3q-amplified Human Cancer
openMay 31, 2031$388,546 - $388,546
Using Artificial Intelligence to Estimate Personal Symptom Network for Cancer Survivorship Care
openMay 31, 2028$491,925 - $491,925
Engineering Salmonella-based Platforms for Immunotherapy Against Immunologically Silent Tumors
openMay 31, 2028$432,125 - $432,125
Defining Symptom Trajectories to Inform Risk-Stratified Approaches to Symptom Management in Children with Advanced Cancer
openMay 31, 2031$689,340 - $689,340
Longitudinal Radio-pathomic Mapping of Non-Enhancing Tumor Growth in Glioblastoma
openMay 31, 2031$602,121 - $602,121
Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer
openMay 31, 2031$638,771 - $638,771
Multifunctional nanoparticles for improved immunotherapy of melanoma
openMay 31, 2031$640,113 - $640,113
Identifying and characterizing a stimulatory immune checkpoint in macrophage immunosurveillance
openMay 31, 2031$733,864 - $733,864
REWIRING ONCOGENIC PATHWAYS TO INDUCE CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA
openMay 31, 2029$661,135 - $661,135
A novel "cap-linker" strategy to target oncolytic viruses to the tumor
openMay 31, 2031$499,568 - $499,568
Generation of syngeneic, mutation-driven melanomas in an autoimmune-prone mouse to improve therapeutic efficacy without immunotoxicity
openMay 31, 2031$635,581 - $635,581
Exploring autophagy as a cellular response to fusion oncogene-induced stress
openMay 31, 2029$35,446 - $35,446
A Randomized Controlled Trial of Brief Behavioral Activation for Older Adult Cancer Survivors
openMay 31, 2031$731,503 - $731,503
Fragment-based targeting of EMT-mediated resistance in EGFR-mutant lung cancer
openMay 31, 2028$433,256 - $433,256
Investigating the chromatin remodeling complex PBAF in small cell lung cancer
openMay 31, 2031$577,750 - $577,750
Evaluating and Implementing a decision support intervention (DECIDES) for adolescents and young adults newly diagnosed with cancer
openMay 31, 2031$749,133 - $749,133
A Patient-Specific Magnetic Resonance Guided Focused Ultrasound System for Breast Cancer Treatment
openMay 31, 2031$625,791 - $625,791
Translation factor DAP5 selective mRNA translation and m6A mRNA methylation in breast cancer metastasis
openMay 31, 2031$585,482 - $585,482
Defining fatty acid desaturase 2 (FADS2) as a novel therapeutic target in Ewing sarcoma
openMay 31, 2029$42,696 - $42,696
Decoding the stromal niches of antigen-presenting cancer-associated fibroblast in pancreatic ductal adenocarcinoma
openMay 31, 2031$501,803 - $501,803
Elucidating roles of TRPS1 in regulating antitumor immunity
openMay 31, 2031$657,698 - $657,698
EBV Modulation of Genome Stability in B-cell Lymphoma
openMay 31, 2028$117,144 - $117,144
Identification and Characterization of Mutation-Induced Alternative Splicing Events in Cancer Using Multi-Omics Data
openMay 31, 2028$155,500 - $155,500
Topical Therapy for Cutaneous Precancerous Lesions: a Digitally-enabled Randomized Controlled Trial of Fluorouracil compared with Fluorouracil/Calcipotriene
openMay 31, 2031$704,028 - $704,028
Interactive Functional Dynamics of Human K-Ras, Its Oncogenic Mutants and their Binding Partners
openMay 31, 2031$463,692 - $463,692
Evaluating the Impact of a Novel Educational Intervention to Improve Timely Colposcopy Follow-Up and Treatment Among High-Risk Populations
openMay 31, 2031$702,461 - $702,461
Concomitant Inhibition of VAV3 and ERa to Treat High-Risk B-ALL
openMay 31, 2031$683,698 - $683,698
Biomarker Levels and Illnesses Associated with Exposure to Noncombustible and Combustible Tobacco Products in Young Children
openMay 31, 2031$694,182 - $694,182
The MYC Transcription Factor Network: Elucidating Oncogenic and Tumor Suppressive Pathways
openMay 31, 2031$692,368 - $692,368
Spatially Controlled Priming of CAR T Cells in Solid Tumors via Focused Ultrasound
openMay 31, 2029$137,459 - $137,459
Translational Imaging Markers for Metabolic Potentiation of Immunotherapy
openMay 31, 2031$674,339 - $674,339
Evaluating the impact of nicotine pouch characteristics in the context of a combustible cigarette standard on overall tobacco product use
openMay 31, 2031$621,549 - $621,549
Leveraging Health Systems to Optimize Regional Cancer Care Delivery
openMay 31, 2031$293,430 - $293,430
Bioengineering of covalent proteins for nuclear medicine applications
openMay 31, 2031$640,466 - $640,466
Defining the Impact of Tumor Heterogeneity in Intrahepatic Cholangiocarcinoma
openMay 31, 2028$420,399 - $420,399
Regulation of de novo nucleotide synthesis and Glioblastoma response to radiochemotherapy
openMay 31, 2031$656,469 - $656,469
Methods for Microsimulation Model Calibration
openMay 31, 2031$439,639 - $439,639
Targeting Mitochondrial Fusion in Colorectal Cancer
openMay 31, 2029$190,944 - $190,944
Investigating the molecular mechanisms of MYC-driven transcriptional reprogramming of the tumor microenvironment in prostate cancer
openMay 31, 2029$50,114 - $50,114
Dissecting mechanisms by which mRNA vaccines encoding nontumor antigens initiate antitumor immunity
openMay 31, 2031$136,270 - $136,270
Uncovering the formation and function of fusion oncoprotein condensates in translocation renal cell carcinoma
openMay 31, 2031$643,861 - $643,861
Characterizing and therapeutically targeting pH-regulatory mechanisms in the perivascular and infiltrating niches of glioblastoma using amine CEST-EPI and a novel treatment platform
openMay 31, 2031$640,597 - $640,597
Targeting Ribosome Biogenesis as a Non-Genotoxic Chemotherapy Strategy: Mechanistic Characterization of NVL Inhibition by Benzothiazepinones
openMay 31, 2031$639,514 - $639,514
Molecular mechanisms of Ras and Receptor Tyrosine Kinase Convergence on PI3K in cancer
openMay 31, 2031$636,345 - $636,345
Microbial-based cancer therapy armored with membrane-bound cytokines for targeted immune modulation and safety-controlled delivery
openMay 31, 2031$669,278 - $669,278
Perfusion CT for liver radioembolization
openMay 31, 2028$409,141 - $409,141
Unleashing IFN signal transduction to prime HNSCC immunogenicity
openMay 31, 2031$742,382 - $742,382
Reconstructing transposable element activity in cancer via local assembly of long reads
openMay 31, 2028$369,075 - $369,075
Social Networks and Tobacco Cessation in High-Risk Populations
openMay 31, 2031$522,235 - $522,235
Identifying targets to mitigate immunotherapy-associated immune-related adverse events
openMay 31, 2031$703,423 - $703,423
Evaluating the Synergistic Therapeutic Effects of Retinoic Acid and the Proteasome Inhibitors in Neuroblastoma
openMay 31, 2028$467,968 - $467,968
Predicting response to immunotherapy with hyperpolarized 13C MRI
openMay 31, 2028$421,685 - $421,685
Disparities in AML treatment
openMay 31, 2028$422,649 - $422,649
Establishing Claudin-2 as a Biomarker For Surgical Identification of Colorectal Cancer
openMay 31, 2028$409,120 - $409,120
Implementing Remote Symptom Monitoring in U.S. Cancer Care: A Precision, Context-Informed Approach
openMay 31, 2031$168,363 - $168,363
In Vivo Engineering of Virus-Specific T Cells for CAR T Cell Therapy Against Multiple Myeloma
openMay 31, 2031$705,899 - $705,899
Quantitative Predictive Dosimetry for Curative Transarterial Radioembolization
openMay 31, 2028$161,460 - $161,460
Development of Antibody Chelator Conjugates for Targeted Radionuclide Therapy
openMay 31, 2031$648,992 - $648,992
SLC13A3 in tumor resistance to immunotherapy
openMay 31, 2031$544,868 - $544,868
Regulation of anti-tumor immunity by CX3CL1
openMay 31, 2031$518,090 - $518,090
Mechanistic dissection and targeting non-cell autonomous tumor promotion in DICER1 cancer predisposition
openMay 31, 2031$628,073 - $628,073
Defining immune determinants oftransformation in MGUS/SMM
openMay 31, 2031$959,573 - $959,573
Protein glutathionylation is essential for leukemia initiating cell survival.
openMay 30, 2031$533,245 - $533,245
Radiomic phenotypes for invasive and advanced breast cancer
openMay 31, 2031$722,914 - $722,914
Qualitative Training Institute for Enhancing Cancer Research (CancerQTI)
openMay 31, 2031$323,623 - $323,623
Cis-Regulatory Role of Alternative Promoters in Cancer
openMay 31, 2029$40,908 - $40,908
Identification of small molecule activators of Type I interferon signaling for cancer treatment
openMay 31, 2029$771,811 - $771,811
Light-Responsive Inorganic Compounds for Diagnosis and Therapy
openMay 31, 2029$565,569 - $565,569
Energy balance and reproductive health after early-onset colorectal cancer
openMay 31, 2031$518,470 - $518,470
Role of JAK inhibition in quiescent cancer cells and their microenvironment
openMay 31, 2031$523,544 - $523,544
Identifying mechanisms of structural variant-induced gene activation in glioma
openMay 31, 2029$46,939 - $46,939
Cellular and Molecular Mechanisms of Early onset colorectal cancer
openMay 31, 2028$130,490 - $130,490
Transcriptomic, Genomic, and Microenvironmental Heterogeneity in pancreatic precancer: subtyping, classification, and cross-comparison
openMay 31, 2028$123,823 - $123,823
Ultra-rapid tumor burden measurements for molecularly-guided surgery
openMay 31, 2031$703,227 - $703,227
Restoring anti-tumor immunity in chromosomally unstable tumors
openMay 31, 2031$681,818 - $681,818
Targeting Diet-Driven Inflammation for Colorectal Cancer Prevention in High-Risk Adults: A Biomarker-Guided Approach
openMay 31, 2031$654,226 - $654,226
Characterizing the SPOP-BRAF-mTORC1 signaling axis in melanoma pathogenesis
openMay 31, 2031$682,495 - $682,495
Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.
openMay 31, 2031$581,548 - $581,548
Role of p73-mediated DR5 induction in therapeutic response to CDK inhibition.
openMay 31, 2031$560,863 - $560,863
Investigating age-dependent factors in the development and treatment of adrenal cancer
openMay 31, 2031$581,686 - $581,686
Evaluation of genetic and epigenetic determinants of response in patients with accelerated and blast phase Myeloproliferative Neoplasm (MPNs)
openMay 31, 2028$444,590 - $444,590
Interrogating PP2A to understand and treat high-grade endometrial carcinoma
openMay 31, 2031$512,292 - $512,292
Advancing NEMO’s specific MRI detection of residual breast cancer using novel imaging platforms
openMay 31, 2031$484,944 - $484,944
Acetylation modulates T cell receptor signaling
openMay 31, 2031$498,582 - $498,582
Artificial Intelligence-powered Advanced Ultrasound for Early Diagnosis of Intraocular Melanoma
openMay 31, 2031$643,606 - $643,606
Functions and mechanisms of ILC2s in trained immunity
openMay 31, 2031$684,252 - $684,252
Elucidating mechanisms underlying lung cancer lineage plasticity thatfacilitate adaptation and resistance to targeted therapy
openMay 31, 2031$719,951 - $719,951
Defining and exploiting therapeutically the role of the neuropeptide receptor PAC1 in tumor-infiltrating pericytes that drives melanoma progression.
openMay 31, 2031$508,651 - $508,651
Unraveling the Molecular Mechanisms of Immunotherapy-Associated Myocarditis
openMay 31, 2031$706,739 - $706,739
2026 Annual Meeting of the American Society of Pharmacognosy: Elevating Natural Products
openMay 31, 2027$10,000 - $10,000
Naturally Occurring Canine Hemangiosarcoma as a Translational Model for Angiosarcoma
openMay 31, 2031$635,324 - $635,324
Biomimetic Migrating Nanoparticles Targeting Tumor Stroma and Neural Invasion to Improve Pancreatic Cancer Therapy and Pain Control
openMay 31, 2031$602,170 - $602,170
Decoding Long Noncoding RNA Networks in Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
openMay 31, 2028$115,076 - $115,076
Towards Safe and Efficacious Medical Therapy for Patients with Clinically Non-Functioning Pituitary Tumors
openMay 31, 2029$475,401 - $475,401
Elucidating the function of NF2 in NF1 mutant peripheral nervous system tumors.
openMay 31, 2031$681,070 - $681,070
Reducing ReADmissions through Innovative ApplicatioNs of Telemedicine (RADIANT)
openMay 31, 2031$747,660 - $747,660
Leveraging Multimodal Signatures to Personalize Rectal Cancer Radiotherapy Choice
openMay 31, 2031$518,451 - $518,451
Characterizing the XRN1 exoribonuclease as a therapeutic target in non-small cell lung cancer
openNov 30, 2026$182,363 - $182,363
Sidney Kimmel Cancer Center LAPS Institutional Collaboration
openFeb 29, 2032$544,790 - $544,790
Verifiable and Robust Deformable Image Registration for Precision Tracking of Diffuse Glioma Progression
openApr 30, 2028$50,114 - $50,114
Evaluation of Guideline-based Uptake of Indicated Diagnostic exams after AbNormal Cervical cancer screening test in safEty-net settings (E-GUIDANCE)
openApr 30, 2031$286,638 - $286,638
Combinatorial Pulsed Field Alation for the Treatment of Solid Tumors
openApr 30, 2031$590,791 - $590,791
Understanding and Therapeutic Targeting of Extramedullary Acute Leukemia
openApr 30, 2031$716,681 - $716,681
Investigating lipogenesis mediated resistance to cytotoxic therapy in PDAC
openApr 30, 2028$408,829 - $408,829
Human-mouse platform for data-driven patient stratification, target discovery, and validation in GBM
openApr 30, 2031$683,256 - $683,256
Administration and Statistics
openAug 31, 2030$213,767 - $213,767
North American Star Consortium
openFeb 28, 2027$1,770,712 - $1,770,712
Post-Transcriptional Regulation is a Therapeutic Vulnerability of Acute Myeloid Leukemia
openApr 16, 2030$54,107 - $54,107
Identifying Immune Mediators in BRCA1/2 Deficient High Grade Serous Ovarian Cancer
openApr 30, 2029$50,114 - $50,114
Clonal dynamics and non-genetic mechanisms mediating resistance to RAS inhibition
openApr 30, 2029$50,114 - $50,114
Unraveling the immunobiology of tumor-specific T follicular helper CD4 T cells
openApr 30, 2029$33,384 - $33,384
Advancing cancer vaccine design using deep learning to predict peptide-HLA class I binding and immunogenicity
openApr 30, 2030$43,056 - $43,056
Profiling the tissue microenvironment of Large Granular Lymphocyte Leukemia through cellular dynamics and genetic signatures
openApr 30, 2028$39,498 - $39,498
Investigating the role of incretin mimetics in reducing the risk of development and progression of multiple myeloma and its precursor conditions
openApr 30, 2028$466,125 - $466,125
A CRISPR-based sensitive liquid biopsy for endometrial cancer using tumor-derived hallmarks (CRISPR SLEUTH)
openApr 30, 2030$650,513 - $650,513
Bioinspired virus-like nanovaccines boost CAR T and endogenous T cells in tandem against solid tumors with antigen heterogeneity
openApr 30, 2031$737,082 - $737,082
Pre-Leukemic Hematopoietic Stem Cell Clonal Selection by the Adaptive Immune System
openApr 30, 2031$704,636 - $704,636
Axonal Control of Tumor Progression
openApr 30, 2031$694,133 - $694,133
A Randomized Controlled Trial On Improving Prostate Cancer Screening Among Black Men in Oklahoma Using A Community-Based mHealth Approach (Prostate Cancer Genius App)
openApr 30, 2031$592,731 - $592,731
Investigating the role of Cdkn2a in lung adenocarcinoma metastasis
openApr 30, 2028$158,499 - $158,499
Unraveling nonsense-mediated mRNA decay mechanisms in cancer
openApr 30, 2031$479,234 - $479,234
Payload Selection to Maximize Multiple Mechanisms of Action for High Avidity Low Affinity Antibody Drug Conjugates
openApr 30, 2031$646,671 - $646,671
Expand and pull: long-acting IL-7 and oncolytic virus to treat glioblastoma
openApr 30, 2031$645,185 - $645,185
The role of apelin in the skeletal muscle during cancer cachexia development and recovery
openMay 17, 2029$42,647 - $42,647
Optimization of a public neoantigen-based cancer prevention strategy
openMay 31, 2031$659,570 - $659,570
Exploiting Primed Inflammatory Signaling to Target SETD2 Deficient Renal Tumors
openApr 30, 2031$616,624 - $616,624
The International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia
openApr 30, 2027$20,000 - $20,000
Endogenous HOCl-derived chloramines in skin inflammation and photocarcinogenesis
openApr 30, 2028$399,712 - $399,712
Mouse model for solid Epstein-Barr Virus-driven cancers
openApr 30, 2028$394,214 - $394,214
Radiation synthetic combinations in high-risk Ewing sarcoma
openApr 30, 2031$659,028 - $659,028
Elucidation of targetable mechanisms sustaining immunosuppressive neutrophils in the brain tumor microenvironment
openApr 30, 2031$651,940 - $651,940
Immunogenomic determinants of response and resistance to neoadjuvant anti-PD-1 in resectable NSCLC
openFeb 29, 2028$355,706 - $355,706
Development of B-cell-based vaccine for Glioblastoma
openFeb 29, 2028$362,482 - $362,482
Clinical Translation of a Urine-Based Biomarker for the Detection of Residual Disease in Radical Cystectomy Candidates
openApr 30, 2028$263,670 - $263,670
Imaging Goggles for Fluorescence-Guided Surgery
openApr 30, 2031$623,432 - $623,432
Clinical Translation of the First Meitner-Auger PET Theranostic
openApr 30, 2031$641,419 - $641,419
Targeting a novel covalent RAS dimer in RASQ61 mutants-driven cancers
openApr 30, 2029$131,727 - $131,727
Characterizing mutational signatures at hotspots of genetic instability in human cancer genomes
openApr 30, 2028$396,377 - $396,377
Cytokines and B cells controlling immune tumor microenvironment in hepatocellular carcinoma
openApr 30, 2031$695,634 - $695,634
Novel methods for the design, analysis and implementation of ELISpot experiments
openApr 30, 2030$484,387 - $484,387
Sphingolipid-guided stratification and therapeutic opportunities in Acute Myeloid Leukemia
openApr 30, 2029$192,887 - $192,887
Utilizing Glycosaminoglycans as a Theragnostic Approach for Treating Platinum-Resistant Gynecological Malignancies
openApr 30, 2028$399,187 - $399,187
Organoid-immune cell culture modeling of therapeutic responses in cholangiocarcinoma
openApr 30, 2031$628,394 - $628,394
Integrated G Protein Circuitry for Cancer Cell Signaling Autonomy
openApr 30, 2031$637,509 - $637,509
Strategies to improve therapy to pancreatic cancer with targeted-nanoparticle
openApr 30, 2028$401,115 - $401,115
Molecular Mechanisms of Altered DNA Binding and Chromatin Regulation by FET::ETS Oncogenes
openApr 30, 2031$639,295 - $639,295
Prostate Cancer Cohort Consortium (PC3): A collaborative approach to an enigmatic cancer
openApr 30, 2031$62,367 - $62,367
Defining and overriding mechanisms of in vitro and clinical resistance to the first highly active allosteric kinase inhibitor
openApr 30, 2031$700,338 - $700,338
ADAR1 promotes Okazaki fragment maturation and is a target for breast cancer therapy
openApr 30, 2031$367,731 - $367,731
Oxygen Sensing and Ferroptosis in Cancer
openApr 30, 2031$614,260 - $614,260
Cysteine Acquisition and Utilization in Lung Adenocarcinoma
openApr 30, 2031$687,593 - $687,593
Optimizing neoadjuvant/adjuvant anti-PD-1 therapy for localized Renal Cell Carcinoma
openApr 30, 2031$740,020 - $740,020
Interrogating and targeting co-inhibitory and co-stimulatory molecules in CAR T-cell Therapies
openApr 30, 2031$716,183 - $716,183
The Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell Tumor
openApr 30, 2028$431,222 - $431,222
Small molecule inhibitors of the proton-sensing receptor GPR68 for pancreatic cancer therapy
openApr 30, 2028$411,206 - $411,206
Harnessing TLR4 Signaling Pathways in CAR Dendritic Cells to Overcome Tumor Immune Tolerance
openApr 30, 2028$399,829 - $399,829
Dissecting mechanism of EPHX2 deficient Bladder Cancer and targeting metabolic and immunologic vulnerabilities
openApr 30, 2031$681,330 - $681,330
Targeting Tr1 to enhance the efficacy of cancer vaccines
openApr 30, 2028$399,829 - $399,829
Identification of Novel Innate Immune Checkpoint Receptors
openApr 30, 2027$412,249 - $412,249
Improving Treatment Sensitivity through Syk using Novel Translational Models of Uveal Melanoma
openApr 30, 2028$415,000 - $415,000
Protein Degradation Strategies to Overcome Menin Drug Resistance in Acute Leukemias
openApr 30, 2028$399,829 - $399,829
Deciphering the Role of Tumor Suppressor Gene Deficiencies in Modulating PDAC Response to Oncogenic KRAS Inhibition and Immunotherapy
openApr 30, 2028$141,195 - $141,195
Function and Therapeutic Implications of NRG3 in Breast Cancer Brain Metastasis
openApr 30, 2031$642,242 - $642,242
A novel chemical strategy to harness the tumor specific biochemistry of human kallikrein 2 for prostate cancer theranostics
openApr 30, 2031$575,178 - $575,178
AI-Enhanced Perfusion MRI for Optimizing Y90 Particle Density in Radioembolization of Liver Cancer
openApr 30, 2031$640,956 - $640,956
Colorectal Cancer Therapies Introduced Through Engineered Native Bacteria
openApr 30, 2031$671,226 - $671,226
Early detection of liver cancer among patients with cirrhosis and MASLD
openApr 30, 2028$399,829 - $399,829
Personalized Outreach and Multifaceted Interventions for Screening Enhancement (PROMISE) for Anal and Cervical Cancer Prevention and Treatment
openAug 31, 2030$2,336,229 - $2,336,229
Project 2: Adoptive Cell Therapies for Chordomas
openJul 31, 2030$319,676 - $319,676
Developmental Research Program
openJul 31, 2030$284,568 - $284,568
Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer
openJul 31, 2030$2,185,934 - $2,185,934
Core C: Biostatistics and Bioinformatics Core
openJul 31, 2030$250,568 - $250,568
Core A - Administrative & Outreach
openAug 31, 2030$224,008 - $224,008
Project 1: Targeting Tumor Phospholipase PLA2G10 for Cancer Immunotherapy
openJul 31, 2030$411,417 - $411,417
Project 3: Pharmacogenomic advancements for improved treatment of acute lymphoblastic leukemia in Latino children and adolescents
openAug 31, 2030$262,326 - $262,326
Intercellular Communication in Prostate Cancer Progression
openFeb 28, 2031$416,992 - $416,992
Deconstructing and targeting aneuploidy in human cancer
openMar 31, 2028$477,848 - $477,848
Explainable Artificial Intelligence for Melanoma Recurrence Prediction via Integrative Modeling of Multiplexed Imaging with Transcriptomics and Histopathology
openMar 31, 2029$249,000 - $249,000
Cancer Research Training and Education Coordination
openMar 31, 2029$308,953 - $308,953
The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support Grant
openFeb 29, 2032$634,423 - $634,423
Spatial and Clonal Dynamics in Glioblastoma: Disentangling Drivers of Migration and Stemness
openApr 5, 2029$50,114 - $50,114
Exploring ATR as a Novel Vulnerability of Osimertinib-Resistant EGFR-Driven Lung Adenocarcinomas
openApr 6, 2028$35,134 - $35,134
Modeling Minimal Residual Disease in Colorectal Cancer
openMar 31, 2028$415,257 - $415,257
Tumor Microenvironment: Identifying Drivers of Progression and Resistance
openApr 30, 2027$5,000 - $5,000
Investigating the Antioxidant Role of Lipoprotein Uptake in Kidney Cancer
openApr 30, 2027$41,819 - $41,819
Gastroshare: Integrating Electronic Health Systems to Improve the Management ofGastric Precursors across Multiethnic Populations.
openMar 31, 2031$661,643 - $661,643
Engineered mineralized hydrogels to study microcalcifications in breast cancer
openApr 30, 2031$565,909 - $565,909
Purdue Interdisciplinary Cancer Research Training
openApr 30, 2031$164,121 - $164,121
A novel protective role of PYDC5 in colorectal cancer
openApr 30, 2031$679,353 - $679,353
The 11th Annual Midwest Tumor Microenvironment Conference 05/18/2026-05/20/2026
openApr 30, 2027$15,000 - $15,000
Impact of KEAP1/NRF2 on therapy response in lung neuroendocrine cancers
openApr 30, 2031$712,569 - $712,569
Jumonji KDM5 enzymes mediate resistance to CDK4/6 inhibitors in Breast Cancer
openApr 30, 2028$426,828 - $426,828
Functional genomic dissection of lung cancer in vivo
openApr 30, 2031$635,340 - $635,340
Measuring Provider and Intervention Characteristic Determinants of Evidence-Based Cancer Care
openApr 30, 2029$737,945 - $737,945
Reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic adenocarcinoma
openApr 30, 2031$357,370 - $357,370
Cross-species transfer learning for liquid biopsy-based cancer detection
openApr 30, 2028$402,068 - $402,068
Identification of chromatin regulators required for enhancer hijacking in cancer genomes
openApr 30, 2031$795,143 - $795,143
The RUNX1 Research Program 10th Annual Scientific Conference and Patient Meeting
openApr 30, 2027$10,000 - $10,000
Fragment-based drug discovery against oncogenic microRNA precursors using high-throughput crystallography.
openApr 30, 2029$528,265 - $528,265
2026 Nasopharyngeal Carcinoma Gordon Research Conference
openApr 30, 2027$15,000 - $15,000
Single-Cell Signaling Network Profiling of Pooled CRISPR Screens by Mass Cytometry
openApr 30, 2028$406,325 - $406,325
Integrating nutrition and proteomics to improve chemotherapy-induced peripheral neuropathy in cancer survivors
openApr 30, 2028$176,256 - $176,256
Targeting the Hippo-YAP/TEAD Signaling Network in Head and Neck Cancer
openApr 30, 2031$694,643 - $694,643
Accelerated Biological Aging and Immunosenescence as Drivers for Racial Disparities in Monoclonal Gammopathy of Undetermined Significance (MGUS)
openApr 30, 2031$558,016 - $558,016
The mechanism and therapeutic potential of Parkin in colorectal cancer
openApr 30, 2031$542,316 - $542,316
Programmable Multiplexed Detection of Cell-free DNA Mutation for Liquid Biopsy
openApr 30, 2029$414,585 - $414,585
Development of an F-18 Imaging Agent to Measure Glioma IDH1mut Expression
openApr 30, 2028$402,401 - $402,401
Single-cell Joint Profiling of Single- and Double-Stranded DNA Breaks with Transcriptome
openApr 30, 2029$270,683 - $270,683
Exploring LMTK2: A novel mediator of endocrine sensitivity in ER+ breast cancer
openMay 5, 2029$50,114 - $50,114
Immune microenvironment in brain metastais
openApr 30, 2031$554,732 - $554,732
Dissecting Inter-Compartmental Tumor-Host Communication Driving Early Dissemination in Uveal Melanoma.
openApr 1, 2031$573,286 - $573,286
Advanced development and validation of aliquot-level visual indicators of biospecimen exposure to thawed conditions
openApr 30, 2029$353,601 - $353,601
Dual imaging of pHi and pHe to dissociate glycolytic/oxidative phenotypes for novel GBM therapeutics
openApr 30, 2031$607,690 - $607,690
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
openApr 30, 2028$396,881 - $396,881
Deciphering cancer origin from DNA evolution
openMar 31, 2031$428,975 - $428,975
Methodological Training for Social and Behavioral Research in Cancer Control
openApr 30, 2031$162,501 - $162,501
MedMemos: A Program to Promote Medication Adherence in Pediatric Hematopoeitic Stem Cell Transplantation
openApr 30, 2028$406,258 - $406,258
Adaptation and Evolution of Resistance to Pan-RAS inhibition in PDAC
openApr 30, 2031$682,673 - $682,673
Defining the role of MAFG in melanocyte transformation and melanoma development
openApr 30, 2031$607,249 - $607,249
Multiplexed multiscale imaging for cellular immunotherapies
openApr 30, 2029$207,802 - $207,802
Reprograming T cell function through BCL-2 family protein:protein disruption
openApr 30, 2031$588,289 - $588,289
Exploring the Novel Functions of Cyclin Ds in T Cells and Tumor Progression
openApr 30, 2031$643,053 - $643,053
Identifying spatial tumor microenvironment signatures for risk stratification in primary melanoma
openApr 30, 2031$693,290 - $693,290
Northwestern University Lead Academic Participating Site
openFeb 29, 2032$1,139,381 - $1,139,381
Assessing the impact of early physiotherapy on lymphatic dysfunction in breast cancer survivorship
openApr 30, 2031$663,818 - $663,818
Modeling neuroendocrine bladder cancer for studying the pathogenesis and improving chemotherapy responses
openApr 30, 2031$639,379 - $639,379
Bioprinted 3D vascular cancer model
openApr 30, 2031$604,102 - $604,102
Therapeutic Restoration of Cholangiocyte Primary Cilia via Microbiota-Derived Butyrate: A Novel Approach for Bile Duct Cancer
openApr 30, 2028$408,829 - $408,829
Neighborhood Disadvantage and Obesity-Related Cancer Incidence in US Hispanics/Latinos: The Biobehavioral and Social Pathways
openApr 30, 2031$199,584 - $199,584
Investigating the role of cell cycle plasticity in the growth and progression of bladder cancers
openApr 30, 2028$412,856 - $412,856
Multi-Modality Modeling of Glioblastoma Progression: Integrating DTI and Prognostic Biomarkers for Personalized Radiation Therapy Targeting
openApr 30, 2028$414,402 - $414,402
Mapping the m3C epitranscriptome in cancer
openApr 30, 2028$167,500 - $167,500
Targeting cell death pathways to prevent KRAS inhibitor resistance
openApr 30, 2028$166,000 - $166,000
Single-Cell Multi-omics 3D Genome Technology for Cancer Structure Variation and Enhancer Hijacking
openApr 30, 2029$402,135 - $402,135
The first clinical prototype for proton minibeam radiation therapy
openApr 30, 2031$683,885 - $683,885
Tumor Cell Autonomous and Non-Autonomous Mechanisms of Lipocalin-2 Function in Metastasis
openApr 30, 2029$545,000 - $545,000
POLE-mutant Tumors: Mechanisms of Genomic Instability and Discovery of New Driver Alleles
openApr 30, 2031$584,852 - $584,852
Pangenome-Aware Methods for Accurate Somatic Variant Discovery in Cancer Genomics
openApr 30, 2029$593,867 - $593,867
Targeting non-genetic and genetic mechanisms to overcome drug resistance in acute myeloid leukemia
openApr 30, 2031$639,859 - $639,859
Myeloid Phagocyte Activation by Commensal-Activated Complement C5aR1 Signaling: Implications for Tumor-Directed Lymphocyte Response
openApr 30, 2028$467,261 - $467,261
Risk-Based Prostate Cancer Screening: Perceptions and Informational Needs of Screening-Eligible Men
openApr 30, 2028$160,093 - $160,093
Investigating Type I Interferon response and differentiation in FLT3-inhibitor persistent acute myeloid leukemia
openApr 30, 2031$434,969 - $434,969
New FADS diet for endocrine resistant breast cancer
openApr 30, 2031$625,470 - $625,470
Low Molecular Weight Theranostics for Multiple Myeloma
openApr 30, 2031$591,419 - $591,419
Multilevel, Faith-based Intervention to Promote Rural Physical Activity
openApr 30, 2028$115,420 - $115,420
Medicare Advantage and cancer care for older adults
openApr 30, 2031$649,620 - $649,620
Breaking the Myeloid-Stromal Axis to Treat Colorectal Cancer
openApr 30, 2031$697,131 - $697,131
Functional characterization of the lineage plasticity landscape of cholangiocarcinoma
openApr 30, 2031$510,671 - $510,671
AI-CChaSE: AI-enabled Cancer CHatbots for Symptom Education
openApr 30, 2031$819,628 - $819,628
Investigating the Impact of Obesity and Androgen Receptor Signaling on BRAF/MEKi Resistance in Melanoma
openApr 30, 2031$291,498 - $291,498
Microenvironmental and hepatocyte cell type specific regulation of colorectal cancer metastasis by IL17
openApr 30, 2031$708,990 - $708,990
Identifying Mechanisms of Implementation Strategies for Cancer Control: An Implementation Mapping Approach
openApr 30, 2028$401,115 - $401,115
Randomized Trial of a Dissonance-Based Sun Safety Intervention for Young Adult Tanners
openApr 30, 2030$444,991 - $444,991
Harnessing Androgen-Driven Immune Modulation to Enhance Immunotherapy for Endocrine Cancers
openApr 30, 2028$126,933 - $126,933
Innate & Adaptive Determinants of Post-CAR Cytokine Release Syndrome
openApr 30, 2028$452,540 - $452,540
Optimization of a multicomponent intervention to foster functional recovery after breast cancer treatment
openApr 30, 2031$696,498 - $696,498
Assessing multi-level predictors of diagnostic follow-up attendance after an abnormal cervical cancer screen
openApr 30, 2028$155,000 - $155,000
Biomarker Development and Applications to Inform Cancer Prevention
openApr 30, 2031$309,761 - $309,761
HiJAKing the System: Investigating the Impact Mechanisms of Low Variant Allele Frequency JAK2V617F Clone on the Pathobiology of Myeloproliferative Neoplasms
openApr 30, 2031$688,917 - $688,917
MTAP-MAT2A synthetic-lethality induced by transition state analogs
openApr 30, 2031$692,197 - $692,197
Novel selective allosteric modulators of PTHrP/PTH receptor to inhibit prostate cancer metastases
openApr 30, 2028$418,822 - $418,822
Menin and Ewing Sarcoma Metastasis
openApr 30, 2031$636,097 - $636,097
Microbiome-metabolome signaling interactions reduce obesity-mediated breast cancer risk
openApr 30, 2031$622,071 - $622,071
Proteomics-driven analysis and robotics-enabled drug testing of microdissected tumors and their microenvironment
openApr 30, 2031$686,271 - $686,271
Investigating T cell Circuits in the Lymphatic System During Melanoma Progression
openApr 30, 2031$695,852 - $695,852
Spatiotemporal molecular elucidation of radiation-induced tumor microenvironment remodeling to en-hance immunotherapy in head and neck cancer
openApr 30, 2031$715,710 - $715,710
Spatial heterogeneity of Her2 expression in luminal breast cancer
openApr 30, 2031$646,208 - $646,208
Therapeutic Targeting of Upregulated BAP1 in Human Hepatocellular Carcinoma
openApr 30, 2028$402,401 - $402,401
Lung Cancer Care and Prognosis: Medicare Advantage vs Traditional Medicare
openApr 30, 2031$425,088 - $425,088
Characterization of the functions of the DNA translocase SMARCAL1 in anti-tumor immunity
openApr 30, 2031$630,089 - $630,089
NEUROD1 and cell fate plasticity in olfactory neuroblastoma
openApr 30, 2031$610,459 - $610,459
Circulating senescent proteins and their trajectories in relation to age-related outcomes in cancer survivors
openApr 30, 2028$399,852 - $399,852
Dissecting the Metabolic Rewiring Mediated by SMARCB1 Loss in Metastatic Bladder Cancer
openApr 30, 2028$160,000 - $160,000
Assessment of efflux transport, pharmacokinetics and systems pharmacology impact on MMAE induced neurotoxicity
openApr 30, 2028$410,545 - $410,545
Development of Novel Biomarkers for Diagnosis of Malignant Pleural Effusion
openApr 30, 2028$449,969 - $449,969
Regulation of tumorigenic G protein signaling by novel post-translational mechanisms
openApr 30, 2029$428,396 - $428,396
The role of ASAH1-driven ceramide metabolism in EBV B-cell transformation under physiologically relevant germinal center hypoxia
openApr 30, 2031$415,994 - $415,994
Leveraging Causal Machine Learning Methods to Enhance Tobacco Control Interventions
openApr 30, 2031$158,895 - $158,895
Defining the role of TTK in neuroendocrine prostate cancer
openApr 30, 2031$607,157 - $607,157
Optimizing Medicaid Managed Care to Improve Access, Quality, and Clinical Outcomes for Patients with Gastrointestinal Cancers
openApr 30, 2031$212,332 - $212,332
Defining the impact of detachment sensing proteins in ovarian cancer metastasis
openApr 30, 2031$638,422 - $638,422
In Vitro Human INtraDuctal (HIND) Model of Early Stage Breast Cancer Progression Heterogeneity
openApr 30, 2029$396,406 - $396,406
Evaluating inherited genetic variation and outcome among children andadolescents treated for acute myeloid leukemia
openApr 30, 2028$339,911 - $339,911
Control of T-cell stemness and T-cell exhaustion by KEAP1-NRF2 axis
openApr 30, 2031$402,011 - $402,011
Defining the cell intrinsic and tumor immune microenvironment mechanisms of DNA-PKcs in radiotherapy resistance in glioblastoma
openApr 30, 2031$286,881 - $286,881
Advancing a novel synthetic lethal target by exploiting ribosomal stress in Ch9p21.3-deleted or MSI-H cancers
openApr 30, 2031$501,422 - $501,422
3D Bioprinted In Vitro Model: A New Research Tool for Investigating Bidirectional Communication in Chondrosarcoma
openApr 30, 2028$154,917 - $154,917
Overcoming chronic inflammation-driven T cell quiescence in gastric adenocarcinoma
openApr 30, 2031$730,097 - $730,097
Role of ATAD2 in Prostate Cancer Progression and Metastasis
openApr 30, 2031$682,886 - $682,886
The biology and phenotypic consequences of B-cell clonality driven by mosaic chromosomal alterations
openApr 30, 2031$235,491 - $235,491
Novel Antibody-drug Conjugates for Gamma-Delta T-cell Cancers
openApr 30, 2031$644,632 - $644,632
Vision-Language Models with Explainability for Breast Cancer Prognosis using Image and Clinical Data.
openApr 30, 2031$825,627 - $825,627
Methylation Changes in Viral and Host DNA in Blood as Biomarkers for Early Detection of Lymphomagenesis in HIV-Infected Individuals
openApr 30, 2031$677,621 - $677,621
Understanding Tumor Suppressive Functions of Protein Phosphatase 2A
openApr 30, 2031$651,038 - $651,038
Stanford Cancer Research Education Program (SCREP)
openApr 30, 2031$140,670 - $140,670
A pilot adaptive trial of FITtrack chatbot, nurse navigator, and peer navigator to promote FIT screening among rural residents.
openApr 30, 2028$380,554 - $380,554
Characterizing the cooperative role of E2F1 and interacting proteins in driving advanced prostate cancer
openApr 30, 2028$169,291 - $169,291
Metabolic Gatekeeping of Dormancy in Disseminated NSCLC Subpopulations
openApr 30, 2031$572,378 - $572,378
Spatial and functional profiling tumor evolution trajectories and microenvironment interactions of VHL driven renal cancers
openApr 30, 2028$131,933 - $131,933
Exploring host GSK3β-53BP1 axis in immune control of solid tumor progression
openApr 30, 2031$628,980 - $628,980
A novel combination therapy for recurrent ovarian cancer
openApr 30, 2028$403,686 - $403,686
The Massey/VCU’s McCaskill-Stevens K12 for Community Oncology and Prevention Research
openApr 30, 2031$54,000 - $54,000
Project 2
openAug 31, 2030$416,073 - $416,073
Roles of mRNA transfer in cancer cell-platelet communication
openNov 30, 2028$294,940 - $294,940
Dual targeting of AML by BCL-2 inhibition and by CD123-directed NK engager/NK cell immune therapies
openMar 31, 2028$431,970 - $431,970
Establishing Ethical Standards for Informed Consent and Counseling for Multi-Cancer Early Detection Testing
openMar 31, 2028$134,919 - $134,919
Development of autologous humanized leukemia models for immunotherapy testing
openMar 31, 2031$573,262 - $573,262
Building upon a tradition of excellence. The NCTN at IUSCCC
openFeb 29, 2032$366,921 - $366,921
Abramson Cancer Center Lead Academic Participating Sites (LAPS)
openFeb 29, 2032$368,701 - $368,701
Large-scale artificial intelligence using radiomics, deep learning, and physics-based generative modeling to improve clinical outcomes in nuclear medicine
openDec 31, 2028$249,000 - $249,000
An Integrated Image-Enabled Computational Model for Lung Cancer Intratumoral Therapy
openMar 31, 2031$595,012 - $595,012
Identifying immune-mediated mechanisms of RAS inhibitor efficacy and resistance in pancreatic cancer
openMar 31, 2028$384,630 - $384,630
Macrophage-directed strategies for BRCA-associated breast cancer
openMar 31, 2031$772,208 - $772,208
Investigating BCAA oxidation and signaling in macrophages to drive anti-tumor immunity in PDAC
openMar 31, 2031$780,764 - $780,764
2026 Annual Conference Grant: American Society of Preventive Oncology
openMar 31, 2027$40,000 - $40,000
Metabolic Imaging Using Hyperpolarized Agents at Tracer Concentrations
openMar 31, 2028$415,623 - $415,623
Disrupting the Peri-necrotic Engine of Immunosuppression in Glioblastoma
openMar 31, 2031$496,357 - $496,357
Targeting tumor architecture as a novel therapeutic strategy for pancreatic cancer
openJan 31, 2028$458,086 - $458,086
Energy balance, mTOR pathway signaling, and breast cancer prognosis
openJan 31, 2028$766,371 - $766,371
Roles of Hsp47 in breast cancer progression
openJan 31, 2028$267,208 - $267,208
Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma
openFeb 29, 2028$554,814 - $554,814
Mechanisms of immunosuppression triggered by checkpoint blockade immunotherapy
openMar 31, 2031$648,626 - $648,626
Protoacoustic Imaging for 3D Mapping the Bragg Peak in Real Time during Proton Therapy
openMar 31, 2031$648,049 - $648,049
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.
openMar 31, 2028$538,178 - $538,178
Novel Treg inactivating approach for cancer immunotherapy via targeted protein degradation
openMar 31, 2031$482,312 - $482,312
The Role of Clonal Hematopoiesis in Lung Cancer: Immune Dysregulation and Therapeutic Targeting
openMar 31, 2031$646,181 - $646,181
Type 1 Innate Lymphoid Cells: Mechanisms and Anti-AML Potential
openMar 31, 2031$586,364 - $586,364
Targeting androgen-driven resistance to immune checkpoint inhibitors in pancreatic ductal adenocarcinoma
openMar 31, 2028$402,401 - $402,401
Development of miRNA-based approach for pediatric high-grade gliomas
openMar 31, 2031$544,520 - $544,520
Discerning the role of CDK10 in driving aggressiveness and disparities of triple negative breast cancer
openMar 31, 2028$403,686 - $403,686
Proline tRNA biogenesis as oncogenic drivers and therapeutic target in T cell acute lymphoblastic leukemia
openMar 31, 2031$473,372 - $473,372
Pre-Clinical Evaluation of a Highly Selective SMARCA2 Degrader in Therapy-Resistant Triple-Negative Breast Cancer
openMar 31, 2028$398,544 - $398,544
Durability of memory T cell responses in melanoma
openMar 31, 2031$660,808 - $660,808
Investigating mechanisms of CD8 T cell differentiation in the tumor-draining lymph node
openMar 31, 2031$696,189 - $696,189
Targeting oncogenic KRAS to sensitize pancreatic cancer to NK cell immunotherapy
openApr 8, 2030$47,827 - $47,827
2026 Annual Meeting of the American Society for Investigative Pathology
openMar 31, 2027$10,000 - $10,000
Defining the determinants of long term CAR-T persistence
openMar 31, 2031$703,071 - $703,071
Shared Resources Core: Ferroptosis Biomarkers and Lipidomic Analysis
openJul 31, 2030$326,204 - $326,204
Project 3: Development of Novel Antibody Drug Conjugates for the Treatment of Osteosarcoma
openJul 31, 2030$477,912 - $477,912
Epigenomics Core
openMar 31, 2030$394,295 - $394,295
Defining the roles of mutant p53 and Mdm2 in metastasis
openJul 31, 2030$537,052 - $537,052
AIDS and Cancer Specimen Resource (ACSR)
openAug 31, 2026$897,500 - $897,500
Technology Facilitated Behavioral Intervention for Depression among Diverse Patients in Ambulatory Oncology
openFeb 29, 2028$742,929 - $742,929
Data Analytics Training And Professional Development (DATA-Pro) for Behavioral and Social Sciences Research
openFeb 28, 2030$215,976 - $215,976
A microphysiological model of prostate cancer metastasis into vascularized and innervated bone
openFeb 28, 2031$521,002 - $521,002
Defining the pathogenesis of gammaherpesvirus and Plasmodium coinfections
openMar 31, 2031$460,548 - $460,548
Tumor-penetrating stromal modification of β5 integrin-rich pancreatic cancer
openMar 31, 2031$683,970 - $683,970
Rational Design of Next-Generation Engineered T Cells for Enhanced Cancer Immunotherapy
openMar 31, 2028$399,829 - $399,829
Novel Dual Agent HP C-13 MRI for Quantitative Imaging of Prostate Cancer Aggressiveness for Improved Biopsy Guidance
openMar 31, 2031$679,290 - $679,290
Targeting EZH2 in advanced prostate cancer
openMar 31, 2031$497,972 - $497,972
Structure and function related biomarkers and computational models for predicting adenoma recurrence in patients with advanced adenomas
openMar 31, 2028$396,799 - $396,799
Targeting YB-1 to overcome chemoresistance in ovarian cancer
openMar 31, 2031$356,850 - $356,850
Dormancy and Pancreatic Adenocarcinoma Recurrence
openMar 31, 2028$168,000 - $168,000
Targeting CXCR4 and Redox Metabolism for Alpha Particle Therapy of Pulmonary Neuroendocrine Tumors and Carcinomas
openMar 31, 2031$628,280 - $628,280
Emergence of tumor regenerative states during neoadjuvant therapy in locally advanced rectal cancer: selection or adaptation?
openMar 31, 2031$730,398 - $730,398
Modeling extensive cellular variability in glycolytic rates using multiplexed live-cell data
openFeb 28, 2031$648,177 - $648,177
Optimizing Pre-clinical Models of Admantinomatous Craniopharyngioma
openMar 31, 2028$156,000 - $156,000
Stratifying Underlying Risk in the Prostate cancer Active Surveillance Study (SURPASS)
openMar 31, 2031$688,959 - $688,959
MDS-associated U2AF1 mutations induce natural killer cell dysfunction
openMar 31, 2028$435,062 - $435,062
Enhancing drug delivery to treat high-risk neuroblastoma
openMar 31, 2028$457,683 - $457,683
Longitudinal Dynamics of Blood Microbiome and Circulating Tumor Cell in Metastatic Breast Cancer
openMar 31, 2028$170,930 - $170,930
Development of active site directed inhibitors and bifunctional degraders of isocitrate dehydrogenase mutants
openMar 31, 2031$435,788 - $435,788
Investigating the Role of B-cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer
openMar 31, 2031$650,597 - $650,597
Decoding Dural Nociceptors as Drivers of Immune Suppression in Glioblastoma
openMar 31, 2027$390,906 - $390,906
Universal methylated ctDNA markers for minimal residual disease detection and therapy response prediction in colorectal cancer
openMar 31, 2031$662,610 - $662,610
Radiation-guided antibody-drug conjugates for cancer therapy
openMar 31, 2031$542,644 - $542,644
Deciphering the mechanisms of resistance to anti-TROP2 cancer therapy using novel humanized mouse models
openMar 31, 2028$431,970 - $431,970
Understanding mechanisms of immunoevasion by precancer stem cells for breast cancer interception
openMar 31, 2031$680,121 - $680,121
Determining mechanisms of heterogeneous treatment response in glioblastoma using multi-omic and multi-organ approaches
openMar 31, 2031$707,798 - $707,798
Dissecting the role of CPT1C in advanced prostate cancer
openMar 31, 2031$551,328 - $551,328
Understanding plant virus-based adjuvants as therapeutics
openMar 31, 2028$420,505 - $420,505
Therapeutic targeting of SMARCAL1 in therapy-resistant gliomas
openMar 31, 2031$395,846 - $395,846
Drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth
openMar 31, 2031$680,129 - $680,129
The Implementation of Local Flavored Cigar Restrictions
openMar 31, 2031$654,688 - $654,688
Quantification of Focused Ultrasound-Mediated Macromolecular Delivery to Brain Tumors with MRI
openMar 31, 2028$404,349 - $404,349
Explore niche-leukemic stem cell interactions and evaluate niche-directed leukemia treatments
openMar 31, 2031$486,426 - $486,426
Gallium maltolate for the treatment of difficult-to-treat high-grade pediatric brain tumors
openMar 31, 2031$632,314 - $632,314
Discovery and synthesis of cryptic enediynes and microbial cytotoxins
openMar 31, 2031$544,480 - $544,480
A Single, Universal, and Digitally Programmable RF System Enables MRI of Any Nucleus
openMar 31, 2031$712,375 - $712,375
PFAS and liver cancer: linking epidemiological evidence with mechanistic studies
openMar 31, 2031$681,676 - $681,676
Bioengineering for Optimization of Locoregional Treatment of Advanced Melanoma
openMar 31, 2031$610,637 - $610,637
Essential roles of noncanonical signaling of JAK1 and JAK2 in mammary gland development and breast cancer
openMar 31, 2031$371,024 - $371,024
Targeting ASH1L histone methyltransferase in leukemia
openMar 31, 2031$646,881 - $646,881
Intratumor Heterogeneity as a Correlate of Clinical Outcome in Patients Avoiding Radical Cystectomy
openMar 31, 2031$766,439 - $766,439
Targeting mucin-type O-glycosylation for EGFR mutant non-small cell lung cancer
openMar 31, 2031$609,846 - $609,846
Functional Avoidance Liver Stereotactic Body Radiation Therapy Guided by MR Multitasking-driven Abdominal Integrated Imaging (MT-AI2)
openMar 31, 2031$700,838 - $700,838
Regulation of Immunometabolism by the Integrated Stress Response in Cancer
openMar 31, 2031$624,194 - $624,194
Systematic functional mapping and interrogation of oncogenic intrinsically disordered regions
openMar 31, 2031$661,721 - $661,721
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancer
openMar 31, 2031$715,002 - $715,002
Peptide-drug conjugates targeting EGFR for improved efficacy of chemotherapy
openMar 31, 2029$534,925 - $534,925
Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer
openMar 31, 2031$660,541 - $660,541
Bundled Outreach of Multiple Cancer Screenings for Under-screened Populations (BUNDLE)
openFeb 29, 2028$596,996 - $596,996
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
openMar 31, 2031$1,264,356 - $1,264,356
Leveraging radiation to sensitize breast cancers to T-DXd
openMar 31, 2028$402,401 - $402,401
Validation and Credentialing of Patient-Derived Xenograft Models of Hepatocellular Carcinoma Using Patient Level Data
openFeb 28, 2031$667,041 - $667,041
Genome-Wide In Vivo CRISPR Screens in Human T Cells Identify GPCR Pathway Targets to Enhance CAR-T Therapies for Solid Tumors
openMar 31, 2031$680,597 - $680,597
Genetically and metabolically defining high-risk neuroblastoma to exploit effective therapeutic strategies
openMar 31, 2031$608,558 - $608,558
Interrogating Erythroid Differentiation and BCL-XL Axis in TP53-mutated Acute Myeloid Leukemia
openMar 31, 2028$442,816 - $442,816
CD44 splice variants as novel antibody-targets for advanced breast cancer
openMar 31, 2031$668,878 - $668,878
Myeloid cell-derived interleukin 1b promotes chemoresistance in metastatic ovarian cancer
openMar 31, 2028$473,624 - $473,624
Leadership, Planning and Evaluation
openFeb 28, 2030$319,829 - $319,829
Effects of combined FAK inhibition with MAPK blockade in brain metastases from cutaneous melanoma
openMar 31, 2031$634,900 - $634,900
The role of bacterial dysbiosis and its influence on pancreatic cancer cell behavior
openJul 31, 2027$43,582 - $43,582
Engineering CD4+ T cells to develop a novel immunotherapy for pancreatic cancer
openJul 31, 2027$51,038 - $51,038
Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application
openJul 31, 2029$4,394,441 - $4,394,441
Replication Gap Suppression by Translesion Synthesis Promotes Drug Resistance in hard-to-treat cancers
openJul 31, 2027$3,000 - $3,000
Targeting mechanisms of chromatin plasticity to improve the efficacy of epigenetic solid tumor therapy
openSep 1, 2027$3,000 - $3,000
Deep learning based 3D network biology knowledge portal for precision oncology
openJul 31, 2028$413,509 - $413,509
c-MYB overexpression for exhaustion resistant CAR-T cell therapies
openJul 31, 2027$400,000 - $400,000
Exploring the dynamic tumor-immune ecosystem of breast cancer in heterogeneous tumor microenvironments
openJul 31, 2030$531,693 - $531,693
Immune drivers of oncogenic virus progression to cancer in people living with HIV
openJul 31, 2030$544,250 - $544,250
HIV persistence and treatment response in Kaposi sarcoma
openJul 31, 2027$432,098 - $432,098
Support of the North American Association of Central Cancer Registries, Inc. (NAACCR) Annual Scientific Conference
openApr 30, 2029$38,011 - $38,011
Development of Novel Engineered Native Bacteria (ENB) for the Treatment of Familial Adenomatous Polyposis
openJul 31, 2026$392,827 - $392,827
CP-CTNet Coordinating Center
openJul 31, 2031$2,490,206 - $2,490,206
Deep Learning Serial Radiomics for Improved Cancer Therapy Response Assessment.
openJul 31, 2027$1,686,258 - $1,686,258
Non-invasive etiology-adjusted precision liver cancer risk prediction
openJul 31, 2029$2,876,456 - $2,876,456
Deciphering pathogenesis and therapeutic vulnerabilities in germline RUNX1 mutated AML
openJul 31, 2030$495,715 - $495,715
Spotlight on the Cancer Cell: Intrinsic Properties and Vulnerabilities for Therapeutics
openJul 31, 2026$19,800 - $19,800
Explainable Analogical Learning for Oncology Diagnosis and Prediction based on Deep Pathophysiology
openJul 31, 2028$591,468 - $591,468
The role of ENL mutations in kidney development and tumorigenesis
openAug 4, 2028$49,538 - $49,538
Image-guided ethyl cellulose ethanol ablation to enable treatment of cervical dysplasia in low and middle-income countries
openJul 31, 2030$627,148 - $627,148
Principles of Speckle-Based Gene Regulation
openJul 31, 2028$1,749,106 - $1,749,106
Early Integrated Primary and Specialty Palliative Care for Glioblastoma.
openJul 31, 2030$194,940 - $194,940
2025 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar
openJul 31, 2026$8,000 - $8,000
Harnessing natural killer cells for cellular immunotherapy against solid tumors
openJul 31, 2028$1,457,050 - $1,457,050
Regulation of tumor suppression by alpha-ketoglutarate
openJul 31, 2027$990,412 - $990,412
Determining the function of medium to large diameter sensory neurons in paclitaxel-induced pain via large-scale in vivo DRG imaging
openJul 31, 2030$2,714,830 - $2,714,830
New methods to measure and interrupt metabolic fluxes in brain cancer
openJul 31, 2029$2,820,337 - $2,820,337
Improving Affordability in Cancer Care through Economic Screening and Support (I-ACCESS)
openJul 31, 2029$197,747 - $197,747
Image informatics tools for curation and prognostic modeling in pediatric brain tumors
openJul 31, 2028$398,532 - $398,532
Mechanism and therapeutic implication of RNA-modification-mediated codon-biased translation in acute myeloid leukemia
openJul 31, 2030$941,798 - $941,798
The impact of dyadic processes on smoking and cigarette craving: An experimental investigation of romantic partners and smoking friends
openJul 31, 2029$2,202,321 - $2,202,321
CSHL Course on Methods in Cancer Neuroscience (2025-2029)
openJul 31, 2030$213,589 - $213,589
Student-Centered Pathway to Advance Research and Cancer Careers
openJul 31, 2030$324,000 - $324,000
Dyadic and social network influences on health and well-being among young adults with cancer
openJul 31, 2030$197,414 - $197,414
Cross-talk between social determinants of health and MTOR pathway, the missing link in fatigue
openJul 31, 2027$427,085 - $427,085
MEDUSA(GM): an analysis platform for resolving mechanisms of action for anti-cancer drugs
openJul 31, 2028$415,491 - $415,491
Investigation of the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma
openJul 31, 2027$173,500 - $173,500
Determining how cancer cachexia influences gluconeogenesis
openJul 31, 2027$133,955 - $133,955
A dyadic digital skin cancer prevention intervention for adolescents and their parents
openJul 31, 2028$861,930 - $861,930
Educating Social Workers in Palliative and End of Life Care - Oncology
openJul 31, 2030$323,327 - $323,327
Elucidating and overcoming T cell dysfunction in pancreatic cancer
openJul 31, 2030$119,858 - $119,858
Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation: A Pilot Randomized Controlled Trial
openJul 31, 2030$178,453 - $178,453
Program in Cancer Training and Education (PICTE): Preparing the Next Generation of Scientists and Physicians
openApr 30, 2031$169,982 - $169,982
Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia
openJul 31, 2026$399,998 - $399,998
Characterizing DNA Methylation Dynamics in Trisomy 21-Associated Hematopoiesis and Leukemia
openJun 30, 2027$462,454 - $462,454
Strategically Engineered Multi-Antigen KSHV Vaccine: Integrating Humoral and Cellular Immunity for Effective Protection
openJul 31, 2029$4,857,475 - $4,857,475
High throughput multidimensional chemoproteomics for function-directed covalent target discovery
openJul 31, 2028$649,181 - $649,181
Targeted MDM2 degradation for improved treatment for triple-negative breast cancer
openJul 31, 2030$658,561 - $658,561
Cancer Associated Development of Education and Training (CADET) Summer Research Experience
openJul 31, 2030$324,000 - $324,000
Influence of developmental programming in adult stem cells and cancer
openJul 31, 2030$621,570 - $621,570
Colonoscopy augmentation with Fluorescence Lifetime Imaging (FLIm): colorectal cancer detection in humans
openJul 31, 2030$297,074 - $297,074
Cancer Risks from Unregulated Contaminants of Public Water Systems
openJul 31, 2028$376,314 - $376,314
Unraveling the Role of Microenvironmental Chemokines in Beta-Catenin/TCF Signaling and Gene Occupancy during Colorectal Cancer Metastasis to the Liver and Lung
openJul 31, 2028$157,980 - $157,980
Discovery Methods for Functional Immune Niches in Cancer
openJul 31, 2027$421,685 - $421,685
Enhancing anti-PD-1 blockade antitumor efficacy by oncolytic virotherapy-mediated tumor microenvironment immunomodulation
openJul 31, 2027$409,158 - $409,158
Subclonal determinants of radiation response in soft tissue sarcomas
openJul 31, 2030$584,521 - $584,521
The integrated mechanobiology and glycobiology of bone metastasis
openJul 31, 2030$576,337 - $576,337
Controllable solid tumor immunotherapy based on a wireless thermos-activator
openJul 31, 2029$3,036,844 - $3,036,844
A System to Support Development and Success of NCI-Sponsored Trials for Rare Diseases
openJul 31, 2030$122,610 - $122,610
SBIR Concept award for A novel delivery approach to transform metastatic pancreatic cancer treatment and prevention
openAug 10, 2026$354,941 - $354,941
Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy
openJul 31, 2030$616,715 - $616,715
Engineered probiotic bacteria for colorectal cancer immunoprevention and interception
openMay 31, 2027$727,904 - $727,904
Targeting extracellular vesicles in neuroblastoma
openJul 31, 2030$690,013 - $690,013
Generalized and Cancer-Related Episodic Future Thinking for Smoking Cessation: Proof-of-Concept and Feasibility Testing
openJul 31, 2027$395,248 - $395,248
Genome-wide Analysis and Enrichment of Chimeric DNA Fragments in Plasma for Early Detection of Cancer
openAug 10, 2028$36,756 - $36,756
Health Communications for Adults Smoking Nondaily
openJul 31, 2027$164,484 - $164,484
A mixed-methods assessment of decisional needs and development of health communication intervention for anal cancer screening among people with HIV
openJul 31, 2027$181,007 - $181,007
Shark Radiotherapy for the Treatment of Triple-Negative Breast Cancer
openJul 31, 2030$630,171 - $630,171
High-throughput and multiplex single-molecule quantification and sorting of single EV
openJul 31, 2028$625,756 - $625,756
Molecular Transitions Driving AR Loss in Double Negative Prostate Cancer
openJul 31, 2030$655,070 - $655,070
Revolutionizing CAR T-cell Therapy: Enhancing Activity and Persistence of CAR T-cell by Developing a CAR-Enhancer Platform
openJul 31, 2027$1,340,987 - $1,340,987
Pilot Feasibility of DESCANSO: Cognitive Behavioral Therapy for Latino Cancer Patients to Treat the Symptom Cluster Depression, Insomnia and Fatigue
openJul 31, 2030$403,822 - $403,822
Program control of CD8+ T cell response to tumors and tumor memory
openApr 30, 2030$549,460 - $549,460
Socio-environmental Factors, Accelerated Aging, and Cancer Risks and Outcomes in Middle-Aged and Older Adults
openJul 31, 2027$386,612 - $386,612
Development of Personalized Intact Proteome Map for Ovarian Cancer Patients Using Ultrasensitive Multiplexed Top-down Proteomics
openJul 31, 2028$631,621 - $631,621
A randomized trial of charcoal-filtered cigarettes on product perceptions, smoking behaviors, and toxicant exposure
openJul 31, 2030$687,511 - $687,511
A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab
openJul 31, 2028$1,460,952 - $1,460,952
Magnetic Resonance Fingerprinting of Glutamate Metabolism for Guiding Glioma Cancer Care
openJul 31, 2029$3,155,815 - $3,155,815
Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore
openJul 31, 2029$2,491,138 - $2,491,138
FY25 TASK ORDER D - BASE: WO 126680 B539 EAST BASEMENT SWITCHBOARDREPLACEMENT. OPTION 1: 126680A B539 WEST ATTIC SWITCHBOARDREPLACEMENT
openMar 3, 2028$1,980,867 - $1,980,867
DNA Methylation Markers for early detection and monitoring the trajectory of tumor burden in Bladder Cancer
openJul 31, 2027$426,828 - $426,828
Elucidating the functional role and therapeutic potential of GPCR kinase 2 in primary and therapy-resistant basal cell carcinoma
openJul 31, 2030$669,949 - $669,949
Supporting Informed Parental Decisions on HPV Vaccination through Safe and Personalized AI-Driven Conversations
openJul 31, 2029$2,834,092 - $2,834,092
NextGen Oncology Scholars: Nurturing Tomorrow's Pioneers
openJul 31, 2030$159,450 - $159,450
Mechanisms of genetic and non-genetic resistance to KRAS inhibition
openJul 31, 2030$607,849 - $607,849
ROLE OF RNA SEQUESTRATION IN ACUTE MYELOID LEUKEMIA
openJul 31, 2029$2,398,360 - $2,398,360
Conversational Agent to Improve Guideline Concordant Care for People with Cervical Cancer Screening Abnormalities
openJul 31, 2029$3,277,279 - $3,277,279
Preclinical studies for the immunoprevention of multiple myeloma
openMay 31, 2027$704,622 - $704,622
Nanotechnology enabled quantitative imaging of dendritic cell anti-cancer vaccines
openJul 31, 2029$2,628,974 - $2,628,974
Electronic Communication Between Pediatric Caregivers & Healthcare Teams: impact on perceived quality of care
openAug 14, 2027$52,538 - $52,538
Quantifying medical exposures to radiation in children with congenital heart defects using advanced Monte Carlo methods and patient-inspired anatomical models
openAug 15, 2028$45,012 - $45,012
The role of adoptive cellular therapy on myeloid-derived suppressor cell depletion in glioma
openAug 16, 2029$43,727 - $43,727
Extracellular vesicle enclosed circular RNA and interferon responses in tumor host interactions.
openJul 31, 2027$429,399 - $429,399
Integrated Clinical-Grade genomic and pathology AI biomarkers for high-risk prostate cancer
openJul 31, 2030$603,981 - $603,981
Improving Care Delivery for Individuals with Mental Illness and Cancer Across a Cancer Center Network.
openJul 31, 2030$673,096 - $673,096
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
openJul 31, 2030$663,554 - $663,554
Enhancing antitumor efficacy by intratumoral delivering LAIR1 inhibitory signaling
openJul 31, 2027$394,687 - $394,687
Evaluating an outreach strategy to improve the uptake of shared decision-making for lung cancer screening
openAug 15, 2028$43,727 - $43,727
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors
openJul 31, 2027$1,150,000 - $1,150,000
Understanding and Targeting Aberrant RNA Splicing in Leukemia
openJul 31, 2032$1,034,176 - $1,034,176
Clinical Translation of a Choline-targeted NIR dye to guide lung cancer resection
openJul 31, 2030$657,168 - $657,168
Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer
openJul 31, 2030$697,317 - $697,317
InHANCE: Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery
openJul 31, 2030$64,622 - $64,622
Targeting Myeloid Metabolism to Reprogram the Tumor Microenvironment of Glioblastoma
openJul 31, 2029$2,467,799 - $2,467,799
Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients
openJul 31, 2030$684,107 - $684,107
Using germline and somatic genetics to elucidate glioma risk and improve patient outcomes
openJul 31, 2030$484,803 - $484,803
Impact of CAR and Nrf2 dual activation on cyclophosphamide bioactivation and doxorubicin detoxification
openJul 30, 2029$2,840,768 - $2,840,768
The Role and Function of a Novel Signature Gene in BCR::ABL1 (Ph) B-cell Acute Lymphoblastic Leukemia
openJul 31, 2030$517,090 - $517,090
GENES WITH SIGNIFICANT DEFICIT OF LOSS-OF-FUNCTION MUTATIONS IN LUNG TUMOR
openJul 31, 2027$411,404 - $411,404
Targeting the PD-1H (VISTA) Pathway to Overcome Immunosuppression in Acute Myeloid Leukemia
openJul 31, 2030$449,222 - $449,222
Ratiometric Near-Infrared Probes Utilizing BODIPY Dyes for Viscosity and Protein Aggregation Sensing in Live Cells
openJul 31, 2028$576,493 - $576,493
Hypofractionated radiation in combination with B7-H3-CAR T cells for pediatric patients with relapsed/refractory sarcomas
openJul 31, 2030$289,937 - $289,937
Using targeted and non-targeted approaches to examine per- and polyfluoroalkyl substances (PFAS) exposure and glioma risk in young children
openJul 31, 2027$431,377 - $431,377
Defining mechanisms of immunotherapy resistance and targeting TIGIT in hepatobiliary cancers
openJul 31, 2030$270,981 - $270,981
Antidepressant regulation of PDAC
openJul 31, 2030$677,974 - $677,974
Persistent Poverty and Colorectal Cancer Risk: Elucidating biological, behavioral, and place-based pathways
openJul 31, 2030$724,840 - $724,840
FY25 FACILITIES TO G CONSTRUCTION OF BMP STRUCTURES FOR MDE STORM-WATER COMPLIANCE
openMay 19, 2027$2,208,530 - $2,208,530
Genetic technology development for elucidating lineage plasticity mechanisms in cancer
openJul 31, 2030$182,755 - $182,755
Overcoming Resistance to Targeted Therapy in Breast Cancer
openJul 31, 2032$1,056,000 - $1,056,000
Cancer Neuroscience: Crossing Disciplines to Revolutionize Cancer Treatment
openJul 31, 2026$10,000 - $10,000
Development of a Personalized Voxel-wise Prediction of Brain Metastases using Multi-Parametric MR Imaging to Reduce Treatment Toxicity
openJul 31, 2030$729,587 - $729,587
Enhancing Access in Pancreatic Cancer: Examining Facilitators and Barriers to Tertiary Referral for Complex Oncologic Surgical Care.
openAug 21, 2027$94,040 - $94,040
The Ecology of Barrett's Esophagus
openJul 31, 2029$3,130,492 - $3,130,492
HPV Life Cycle and R-loops
openJul 31, 2030$495,374 - $495,374
Training to Prevent Anal Cancer (TPAC)
openJul 31, 2027$165,271 - $165,271
Development of nanoscale infrared spectroscopic imaging for measuring cellular ultrastructure
openJul 31, 2030$573,470 - $573,470
Predicting trajectories of function, cognition, and quality of life among older adults with advanced lung cancer
openJul 31, 2030$658,743 - $658,743
DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung Cancer
openJul 31, 2030$716,521 - $716,521
NCI-F Operations and Technical Support II
openAug 30, 2026$3,683,073 - $3,683,073
RAS Program at FNL
openAug 30, 2026$12,458,414 - $12,458,414
Division of Cancer Treatment and Diagnosis- Operational Task Order
openAug 30, 2026$41,585,966 - $41,585,966
AIDS and Cancer Virus Program (ACVP)
openAug 30, 2026$13,434,098 - $13,434,098
DCEG- GWAS Studies
openAug 30, 2026$1,077,448 - $1,077,448
DCCPS - NCCR Data Platform Supplement
openAug 30, 2026$120,465 - $120,465
DCEG- Molecular Assays for epidemiology studies
openAug 30, 2026$1,392,004 - $1,392,004
DCEG- Repository Services for epidemiology studies
openAug 30, 2026$878,502 - $878,502
Aire-expressing macrophages as novel mediators of tumor immune evasion
openJul 31, 2030$677,787 - $677,787
Informatics Support at FNLCR
openAug 30, 2026$14,306,292 - $14,306,292
New non-Human Primate to study Sexual transmission of HIV
openAug 30, 2026$208,809 - $208,809
DCP - Biospecimen Processing and Trial Logistics
openAug 30, 2026$2,855,659 - $2,855,659
NIEHS - Lung Microbiome Promotes Emphysema by Activating Lung Innate Immunity
openAug 30, 2026$25,131 - $25,131
FY26 FFRDC LEASES
openAug 30, 2026$21,981,436 - $21,981,436
DCP - Clin Trl Info Mgt -DCP Enterprise System Knowledge Base (DESK)
openAug 30, 2026$640,644 - $640,644
Identifying the tissues and tissue features that define the forgiveness window for lenacapavir PrEP in pigtail macaques challenged with HIV
openAug 30, 2026$732,241 - $732,241
HPV Serology
openAug 30, 2026$2,305,845 - $2,305,845
Cryo-EM
openAug 30, 2026$3,405,122 - $3,405,122
DCEG- Genotyping for epidemiology studies
openAug 30, 2026$5,682,112 - $5,682,112
Tregulatory cell-mediated suppression of tumor elimination by NK cells and CD4 T cells
openJul 31, 2030$663,340 - $663,340
DCP - Clinical Trials Regulatory & Monitoring Support for US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network
openAug 30, 2026$500,000 - $500,000
DCP- Cancer Immunoprevention Laboratory Support
openAug 30, 2026$2,156,353 - $2,156,353
Posttranslational regulation of macropinocytosis in pancreatic cancer
openJul 31, 2030$457,503 - $457,503
CGH - Center for Global Health Data Analysis, Technical Support and Dialogues
openAug 30, 2026$1,100,003 - $1,100,003
tRNA modification reprogramming and translational remodeling in cancer
openJul 31, 2030$922,755 - $922,755
NCI-Frederick Operational Support
openAug 30, 2026$82,503,495 - $82,503,495
Pre-synaptic events in homologous recombination and maintenance of genomic stability
openJul 31, 2030$524,815 - $524,815
A novel approach for the use of normal colon organoids in the identification of true casual variants and mechanistic interrogation of their gene targets in colon cancer risk
openAug 31, 2028$192,888 - $192,888
Simultaneously Targeting Lineage Plasticity and Therapy Resistance Drivers Using a Novel Dual-PROTAC Strategy
openAug 31, 2028$192,564 - $192,564
Pfn1’s Role in Genomic Stability and Immune Response in Breast Cancer
openAug 31, 2027$49,538 - $49,538
Targeting p300/CBP in renal cell carcinoma
openAug 31, 2027$483,395 - $483,395
Co-targeting IGF-1R and Glutaminase in Ewing Sarcoma
openAug 31, 2027$391,186 - $391,186
Mechanistic studies on the role of GABA type A ion channel (GABAA) receptors in triple negative breast cancer
openAug 31, 2028$420,600 - $420,600
Biologic rationale of fallopian tube removal to prevent uterine serous carcinoma
openAug 31, 2027$388,256 - $388,256
Recalibrating the Lung Cancer Policy Model to Address Lung Cancer Risk and Lung Cancer Screening Practices in Real-World Populations
openAug 31, 2027$429,399 - $429,399
Cancer and Developing Entrepreneurial Technologies (CADET)
openAug 31, 2030$270,624 - $270,624
Development of an effective, low-cost, point-of-care early detection test for oral cancer in low resource settings
openAug 31, 2027$1,021,347 - $1,021,347
Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning among Advanced Cancer Patients
openAug 31, 2027$744,065 - $744,065
A novel ctDNA analysis solution for the next-generation of liquid biopsy assays
openAug 31, 2026$399,816 - $399,816
Accelerating the expert-crowdsourcing of cancer variant interpretation in CIViC
openAug 31, 2030$809,106 - $809,106
Instituting NCI-funded thyroid and head and neck cancer studies
openAug 31, 2030$201,870 - $201,870
Advancing Treatment for Head and Neck Cancer Patients with Competing Health Risks through Multi-Center Randomized Trials
openAug 31, 2029$988,224 - $988,224
Links between rRNA and tRNA modifications, codon use, translation, and metabolism in cancer cells
openAug 31, 2030$953,922 - $953,922
Defining Intercellular Heterogeneity in Cell Cycle Quiescence
openAug 31, 2028$627,676 - $627,676
Engaging Impactful Immunotherapy Approaches in Renal Cell Cancer Studies
openAug 31, 2030$178,893 - $178,893
Computational Genomics and Cloud Computing at El Paso Community College
openAug 31, 2028$484,764 - $484,764
Novel Models and Biorepository For Early Detection And Therapeutic Intervention Of Pancreatic Cancer
openAug 31, 2030$97,305 - $97,305
NCI Research Specialist (Clinician Scientist) Award
openAug 31, 2030$882,470 - $882,470
Enhancing NCI-funded research at the University of Arizona Cancer Center
openAug 31, 2030$575,051 - $575,051
Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort
openAug 31, 2030$525,013 - $525,013
5mC and 5hmC DNA alterations as sensitive and specific biomarkers for the non-invasive early detection of pancreatic ductal adenocarcinoma
openAug 31, 2030$690,637 - $690,637
A Path Towards Leveraging AI to Enable Point-of-Care MR Devices for Disease Detection
openAug 31, 2030$681,215 - $681,215
A data resource for studying DNA methylation in diverse human tissue types
openAug 31, 2030$816,623 - $816,623
Translational development of osteosarcoma (OS) extracellular vesicle (EV) matrix metalloproteinase (MMP) Activity Assay for assessing patient treatment responses
openAug 31, 2029$2,097,875 - $2,097,875
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial
openAug 31, 2027$1,442,297 - $1,442,297
Simulation, modelling, and estimation of direct and indirect genetic architectures and intergenerational dynamics
openAug 31, 2029$780,113 - $780,113
Cell plasticity in the origin of gastric carcinogenesis
openAug 31, 2027$2,053,139 - $2,053,139
Decoding the Cullin-5 complex to engineer therapeutic T cells with durable effector function
openAug 31, 2030$680,598 - $680,598
Preanalytical Validation of Circulating Tumor DNA from Surgical Drain Fluid as a marker of Postoperative Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma
openAug 31, 2030$360,643 - $360,643
Developing Multispecific T cell Engaging Therapy for Mixed Phenotype Acute Leukemia
openAug 31, 2027$434,361 - $434,361
Discovering Fusobacterium nucleatum's Impact on Breast Cancer Progression and Treatment with POx Micelle Technology
openAug 31, 2027$399,829 - $399,829
Dissecting clonal determinants of platinum/PARP inhibitor cross-resistance in ovarian cancer
openAug 31, 2027$164,000 - $164,000
Advancing Precision Oncology with Scalable Software Solutions for Clinical Variant Interpretation and Expert Curation
openAug 31, 2028$155,500 - $155,500
Expanding access and enrollment to precision medicine trials in Acute Myeloid Leukemia
openAug 31, 2030$135,949 - $135,949
Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer
openAug 31, 2030$730,398 - $730,398
Understanding interplay between the Hsp70 chaperone code and Cyclin D1/Cln3
openAug 31, 2027$150,784 - $150,784
Exploring palmitoylation dynamics: impacts on Cadherin-Catenin adhesion and lipid metabolism in the progression of melanoma lung metastasis
openAug 31, 2030$487,468 - $487,468
"Charting cellular attraction-based interactome with Multivalent Adhesive Probe AFM (MAPA)"
openAug 31, 2028$635,749 - $635,749
A prospective study of circulating autoantibodies and breast cancer risk in the NYU Women’s Health Study
openAug 31, 2030$703,423 - $703,423
Ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics.
openAug 31, 2028$672,371 - $672,371
Validation, translation, and clinical implementation of a gene expression biomarker to predict meningioma outcomes and radiotherapy responses
openAug 31, 2028$315,066 - $315,066
Developing a Certificate in Computational Genomics and Biomedical Data Science
openAug 31, 2028$486,000 - $486,000
Single-cell (phospho-)proteomics platform for functional analysis of tumor microenvironment
openAug 31, 2028$450,904 - $450,904
Programmable nucleic acid cytometry for unraveling heterogeneity in tumors and therapies
openAug 31, 2028$418,176 - $418,176
Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.
openAug 31, 2027$251,360 - $251,360
Cancer Immunoprevention Network (CIP-Net) Resource Coordinating Center
openAug 31, 2030$825,857 - $825,857
Understanding omega-3 and 6 fatty acid dependent regulation of inflammatory signals in pancreatic cancer
openAug 31, 2030$745,320 - $745,320
Functional signatures of post-infusion CAR T cells for early indication of patient response
openAug 31, 2026$399,625 - $399,625
An Integrated Curriculum that Supports Genomic Data Education
openAug 31, 2028$483,620 - $483,620
The BRCA Exchange Knowledgebase for Clinical Cancer Genetics
openAug 31, 2030$660,079 - $660,079
Transforming Mammography With STARLIGHT, Imagine Scientific's Monochromatic X-Ray Imaging System
openAug 31, 2027$779,658 - $779,658
Stiffness-mediated genetic selection of cells
openAug 31, 2030$556,865 - $556,865
Point of care diagnostic to improve access to gynecological screening in low-resource settings
openAug 31, 2026$400,000 - $400,000
AI-powered engineering and analysis of cyanobacterium vesicles targeting gastrointestinal cancer
openAug 31, 2026$400,000 - $400,000
Efficient, cost-effective, and ultrasensitive sequencing of somatic mutations and methylation
openAug 31, 2028$369,468 - $369,468
Flow-informed therapy for glioblastoma
openAug 31, 2030$522,491 - $522,491
The role of adverse social-biological interactions in acute myeloid leukemia disparities
openAug 31, 2030$726,828 - $726,828
PILOT PROJECT 2: Understanding the biology of an ADCK4-NUMBL fusion in lung adenocarcinoma aggressiveness
openAug 31, 2028$144,604 - $144,604
FULL PROJECT 1 - Circulating Immune Cell Profiles, Immune Biomarkers and Lung Cancer Risk
openAug 31, 2026$112,808 - $112,808
Translating Insights in Follicular Lymphoma for Improved Diagnosis and Classification
openAug 31, 2030$714,110 - $714,110
AI for Differentiation of Low vs High Risk Thyroid Nodules on Ultrasound
openAug 31, 2029$2,867,231 - $2,867,231
A Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer
openAug 31, 2027$858,089 - $858,089
Mechanistic Dissection and Modulation of Cytoskeletal Regulation to Overcome Innate Resistance to KRAS Inhibition
openAug 31, 2030$375,150 - $375,150
CD4+ T Cell Activating Hydrogels for Cancer Immunotherapy
openNov 30, 2027$49,538 - $49,538
Early detection of cancer using extracellular vesicle-based liquid biopsy enhanced by priming agents
openAug 31, 2029$54,538 - $54,538
Chimeric Antigen Receptor Modified Natural Killer Cells for the Treatment of Solid Tumors
openAug 31, 2028$192,564 - $192,564
The impact of aberrant m5C mRNA modification on translation initiation and cancer
openAug 31, 2028$75,052 - $75,052
The oncogenic roles of alarmins and monocytes in triple negative myelofibrosis
openAug 31, 2028$157,248 - $157,248
Evaluating the Interplay of Structural, Social, and Spatial Factors in Ovarian Cancer Survival Disparities in California
openAug 31, 2028$44,826 - $44,826
The role of genetic and epigenetic variation in the progression of IDH mutant gliomas
openAug 31, 2028$169,884 - $169,884
Neutrophil-driven pro-recurrent niche formation in mammary adipose tissue
openAug 31, 2026$49,538 - $49,538
Interrogating Mechanisms of Suppressed Tpex Immunotherapy Response in Metastatic Tumor-Draining Lymph Nodes
openAug 31, 2028$42,057 - $42,057
Extrachromosomal DNA as a driver of heterogeneity and plasticity in glioblastoma
openAug 31, 2027$48,515 - $48,515
Exploiting Homologous Recombination Defects with a Novel DNA-Crosslinking Strategy
openAug 31, 2027$49,538 - $49,538
Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade therapy
openAug 31, 2028$183,600 - $183,600
Investigating the role of OAADPr-ACADM interaction in colorectal cancer
openAug 31, 2027$46,462 - $46,462
The Role of Treg and Tpex Interactions in Tumor-Draining Lymph Node Immunosuppression and Immunotherapy Response
openAug 31, 2028$40,513 - $40,513
NCI Research Specialist (Clinician Scientist) Award for Improving Cancer Screening and Clinical Trial Enrollment
openAug 31, 2029$361,695 - $361,695
DeepSRH: Transforming Molecular Cancer Screening with Stimulated Raman Histology and Deep Neural Networks
openAug 31, 2029$2,284,054 - $2,284,054
Project-3: Targeting Hedgehog Signaling Pathway in Breast Cancer Therapy
openAug 31, 2026$146,725 - $146,725
UCCC P30 Supplement: Human Endogenous Retrovirus-H as a Target for Early-Onset Colorectal Cancer
openAug 31, 2026$156,000 - $156,000
Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication
openAug 31, 2027$2,683,351 - $2,683,351
Quit4Life+: Adapting and Evaluating a Phone-Based Tobacco Use Cessation Program for People Living with HIV in Uganda and Zambia
openAug 31, 2026$410,433 - $410,433
A randomized trial of cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma and pre-existing cardiomyopathy or prior anthracycline exposure
openAug 31, 2030$818,625 - $818,625
Analytical and Clinical Validation of an H3K27M ctDNA Assay for Diffuse Midline Glioma (DMG) Surveillance
openAug 31, 2027$210,600 - $210,600
Investigating the Effect of Caspases and Anti-Viral Responses on KSHV Tumorigeniesis
openAug 31, 2027$216,013 - $216,013
RNA Processing in Cancer: From Bench to Bedside
openAug 31, 2026$15,000 - $15,000
Dissecting the structure-function relationship of the Wnt destruction complex condensate
openAug 31, 2027$402,400 - $402,400
pA-regulator controlled, JMJD6 reprogrammed GPC3-CAR T cells for patients with hepatocellular carcinoma
openAug 31, 2027$470,759 - $470,759
Development of new Pt-based ROS storm inducing polymers with tumor specific toxicity
openAug 31, 2027$403,485 - $403,485
NMR strategies to probe allosteric effects of inhibitor binding on AML-associated Src-family kinases
openAug 31, 2027$151,920 - $151,920
Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic
openAug 31, 2026$276,544 - $276,544
Advancing Extracellular Vesicle Therapy for Brain Cancer
openAug 31, 2026$305,031 - $305,031
Molecular Screening for Human Papilloma Virus (HPV) Associated with Cervical Cancers in LMIC Environments
openAug 31, 2026$306,872 - $306,872
Next generation platforms for interrogating TCR specificity
openAug 31, 2028$368,294 - $368,294
Discovery of the mechanisms governing Natural Killer T-cell activation and therapeutic potential in cancer
openAug 31, 2027$39,113 - $39,113
Determining the role of nuclear integrity loss surveillance in PARPi-inducedcell death in BRCA1-deficient cancer
openAug 31, 2027$49,538 - $49,538
CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment
openAug 31, 2026$400,000 - $400,000
Investigating and targeting NSD2 mutation-driven leukemia transformation
openAug 31, 2030$484,405 - $484,405
Clinical Trials Specialist in NCI Clinical Trials Research
openAug 31, 2030$193,926 - $193,926
Preparing IND filing for novel lung cancer therapeutic
openAug 31, 2026$249,815 - $249,815
System for Malignant Lymph Node Identification
openAug 31, 2026$306,798 - $306,798
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults with Cancer
openAug 31, 2030$763,161 - $763,161
Development and piloting of an intervention to reduce the impact of opioid stigma in cancer pain
openAug 31, 2027$145,746 - $145,746
Bioethics research to understand engagement in decision-making among adolescents and young adults with cancer at risk for health care disparities
openAug 31, 2026$178,000 - $178,000
Tumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genes
openAug 31, 2027$906,000 - $906,000
Connectivity mapping identified novel combination therapy for glioblastoma
openAug 31, 2027$891,835 - $891,835
TYK2 Fusions in Lymphoma
openAug 31, 2029$3,111,184 - $3,111,184
Developing methods for advancing the early detection of pancreatic ductal adenocarcinoma leveraging electronic medical records data
openAug 31, 2030$739,640 - $739,640
PRSS1 Mutation and Pancreatic Cancer Tumorigenesis
openAug 31, 2027$850,552 - $850,552
Initiation of Diffuse and Intestinal Non-Cardia Gastric Cancer
openAug 31, 2027$98,559 - $98,559
Early-Life Enterotoxigenic Bacteroides fragilis Acquisition and Colorectal Cancer Risk
openAug 31, 2026$83,224 - $83,224
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
openAug 31, 2028$2,054,733 - $2,054,733
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
openAug 31, 2027$1,152,768 - $1,152,768
Building a Systems Immunopeptidomics Framework to Challenge the Current T Cell Activation Paradigm
openAug 31, 2028$1,512,500 - $1,512,500
Understanding eosinophilic esophagitis-mediated inhibition of esophageal cancer
openAug 31, 2027$36,264 - $36,264
Precision single-cell mapping of chromatin-associated protein activity by molecular footprinting to chart disruptions to gene regulation and dissect tumor heterogeneity in cancer
openAug 31, 2028$401,829 - $401,829
New approaches to targeting cell cycle proteins for cancer treatment
openJul 31, 2032$855,249 - $855,249
Assessing feasibility and acceptability of a multifaceted EHR-integrated mobile health intervention following radical cystectomy
openAug 31, 2027$682,272 - $682,272
Fluorescent Biosensors for measuring the signaling kinetics of GPCR ligands that activate G12/13 pathways.
openAug 31, 2026$364,367 - $364,367
Administrative Supplement to Cancer Center Support Grant (CCSG)
openAug 31, 2026$194,998 - $194,998
Biological factors driving clinical outcomes in HPV+ oropharyngeal cancer
openAug 31, 2030$510,650 - $510,650
Gastroesophageal junction stem cells as the origin of Barretts esophagus and cancer
openAug 31, 2027$1,944,000 - $1,944,000
Proposal for NCI Research Specialist (Clinician Scientist) Award
openJun 30, 2029$375,025 - $375,025
Dissecting the Functional Role of PAX5 Mutations in B-cell Acute Lymphoblastic Leukemia
openAug 31, 2030$483,110 - $483,110
Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia
openAug 31, 2026$400,000 - $400,000
Electrical impedance myography (EIM) to detect and track cancer cachexia
openAug 31, 2027$263,052 - $263,052
Next generation T cell therapies for mutant KRAS solid tumors
openAug 31, 2028$2,238,704 - $2,238,704
Receipt of Guideline Concordant Surveillance in Young Colorectal Cancer Patients.
openAug 31, 2027$82,540 - $82,540
2025 Cancer Cachexia Conference: Cachexia management today and potential treatments for tomorrow
openJun 30, 2026$35,000 - $35,000
Evaluation of Cardiovascular Health Outcomes among Survivors 2 (ECHOS-2)
openAug 31, 2030$772,418 - $772,418
Etiology and Tumor Characteristics of Early-onset Pancreatic Cancer
openAug 31, 2028$191,700 - $191,700
Develop a novel multi-approach dynamic Spot Scanning Proton Arc optimization framework
openAug 31, 2029$498,372 - $498,372
Effectiveness and implementation of a decision support tool to improve surgical decision making in young women with breast cancer
openAug 31, 2027$1,215,184 - $1,215,184
Harnessing big data to understand the confluence of HIV and cancer stigma in the US Southeast
openAug 31, 2030$851,463 - $851,463
AI algorithm development for cervical cancer screening in low resource settings
openAug 31, 2027$371,161 - $371,161
Exploring anti-sense RNAs in melanocyte transformation and melanoma formation
openAug 31, 2027$433,256 - $433,256
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma
openAug 31, 2027$1,204,605 - $1,204,605
Conditional Agonism: PD1-Dependent Activation of 4-1BB for Enhanced Safety
openAug 31, 2027$153,959 - $153,959
Dual localization of angiopoietin like protein 4 in the extracellular milieu and nucleus regulates the hematogenous brain metastasis of triple negative breast cancer
openAug 31, 2028$408,259 - $408,259
Biological and clinical significance of spatial immune heterogenenity in non-small cell lung cancer
openAug 31, 2027$478,532 - $478,532
Deciphering novel UPS regulation of Sgf73/ataxin-7 in controlling SAGA and associated functions in gene expression
openAug 31, 2028$445,500 - $445,500
Translating the tumor regulome from cell-free DNA for precision oncology
openAug 31, 2027$1,056,000 - $1,056,000
Elucidating the interplay between H3K27M variants and DNA damage repair in diffuse midline glioma
openAug 31, 2027$42,480 - $42,480
Decoding the regulation and function of GZMK within tumor-infiltrating CD8+ T cells
openAug 31, 2027$42,480 - $42,480
Biomarker discovery in colon cancer through next-generation metabolomics
openAug 31, 2027$881,647 - $881,647
Investigating evolutionary antagonism between tumors and lymphocytes
openAug 31, 2028$49,538 - $49,538
Direct activation of STAT5 to improve T cell therapeutics
openAug 31, 2027$42,545 - $42,545
Engineered Living Materials as Programmable Therapeutic Implants for Pancreatic Cancer
openAug 31, 2026$137,995 - $137,995
Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery
openAug 31, 2026$356,500 - $356,500
Immuno-modulating Diffuse Midline Glioma by Epi-transcriptomic Reprogramming
openSep 1, 2029$54,538 - $54,538
The role of SUV39H1 in maintaining heterochromatin architecture and identity in Acute Myeloid Leukemia
openAug 31, 2028$44,751 - $44,751
Modified Thrombin Binding Aptamer Treatment of CRC Metastasis
openAug 31, 2026$399,968 - $399,968
The role of loss of Y chromosome across the prostate cancer continuum
openAug 31, 2027$129,058 - $129,058
Modulating costimulation in CAR T cells to enhance antitumor efficacy
openAug 31, 2027$35,090 - $35,090
Elucidating the role of type 2 conventional dendritic cells in shaping anti-tumor immunity
openNov 30, 2028$49,538 - $49,538
Mutation specific pan-KRAS inhibitor signaling responses and anti-tumor effect
openAug 31, 2028$188,351 - $188,351
Engineering diverse commensal skin bacteria for targeted immunotherapy
openAug 31, 2027$443,564 - $443,564
Transforming prostate cancer diagnosis: Feasibility testing of a novel system for integrated endorectal MRI and in-bore biopsy
openAug 31, 2026$399,995 - $399,995
Immune Evasion through HLA-E in Diffuse Large B-Cell Lymphoma: Defining Its Regulation and Cellular Interactions
openAug 31, 2030$241,884 - $241,884
IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents
openAug 31, 2027$984,830 - $984,830
DLK1 as a novel target for Down syndrome myeloid leukemia
openAug 31, 2027$1,273,073 - $1,273,073
Illuminating the subcellular localization and regulation of D-2-hydroxyglutarate using a novel genetically encoded fluorescent biosensor
openAug 31, 2026$462,153 - $462,153
Characterization of HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity via Fc Receptor (CD16a) blockade
openAug 31, 2027$115,000 - $115,000
Leveraging Nanoparticle Interactions with Host Immune Cells to Detect and Treat Cancer
openAug 31, 2030$144,193 - $144,193
SCH: Graph-String Transformer and Reinforcement Learning for Design of Cancer Theranostics
openAug 31, 2029$300,001 - $300,001
Early-life exposures to extreme weather-related factors and pediatric thyroid cancer risk
openAug 31, 2027$431,386 - $431,386
Using Vagal Nerve Stimulation in Conjunction with NRT for Smoking Cessation
openAug 31, 2027$411,939 - $411,939
FY25 FACILITIES TO E - 126663 B539 MISC SAFETY UPGRADES
openApr 6, 2027$1,676,963 - $1,676,963
RISE: Reducing Cancer and HIV Stigma through Empowerment
openAug 31, 2030$24,468 - $24,468
SCH: Wireless sensing of biomarkers using intelligent surfaces for smart homes and sleep medicine
openAug 31, 2029$974,377 - $974,377
Enhancing access in breast cancer prevention clinical trials
openAug 31, 2030$135,951 - $135,951
Implementation science to scale and sustain tobacco treatment leveraging point of care paradigm and health information technology
openAug 31, 2027$1,594,797 - $1,594,797
DIRECT TO PHASE II SBIR CONCEPT AWARD FOR NOVEL IONTOPHORETIC DRUG DELIVERY DEVICE FOR LOCAL AND EFFECTIVE TREATMENT OF ORAL CANCER
openSep 4, 2027$2,995,581 - $2,995,581
Therapeutic targeting and biophysical characterization of CAR-mediated trogocytosis
openAug 31, 2027$422,799 - $422,799
CSHL 2025 Conference on Biology of Cancer: Microenvironment and Metastasis
openJul 31, 2026$30,000 - $30,000
SBIR CONCEPT AWARD FOR DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS
openSep 4, 2026$354,957 - $354,957
Translation of Evolved Oncolytic Virotherapy Product for Colorectal Cancer Treatment
openAug 31, 2026$306,871 - $306,871
Extensions of the SEER-Medicare database: A Critical Opportunity to Answer Real World Questions about the Delivery of High Quality Cancer Care
openAug 31, 2030$130,301 - $130,301
Development of deazaflavin analogs as potent and selective MRP1 inhibitors for cancer chemosensitization
openAug 31, 2027$395,973 - $395,973
Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma
openSep 4, 2028$78,040 - $78,040
SBIR TOPIC: DEVELOPMENT OF DEVICES, DIAGNOSTIC TECHNOLOGIES, OR DIGITAL HEALTH TOOLS FOR TREATMENT, DETECTION, AND DIAGNOSIS OF PEDIATRIC CANCERS AND/OR RARE CANCERSPHASE I CONCEPT TITLE: EVALUATING
openSep 4, 2026$506,498 - $506,498
IPP NCI FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACT TO-F
openFeb 29, 2028$2,532,970 - $2,532,970
Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors
openAug 31, 2027$703,321 - $703,321
Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through murine studies to enable further clinical advancement in non-small-cell lung cancer
openAug 31, 2026$406,500 - $406,500
Rare Tumor Clinical Research Specialist
openAug 31, 2030$197,518 - $197,518
Evaluate the role of extracellular vesicles in tumor microenvironment modulation
openAug 31, 2027$148,500 - $148,500
Noncovalent interaction of mutant KRAS inhibitors
openAug 31, 2027$411,152 - $411,152
Patient-directed technology for non-pharmacologic management of cancer pain
openAug 31, 2026$404,295 - $404,295
Facilitating Scale-Up and Sustainment of High-Quality Lung Cancer Screening Using the QUILS System
openAug 31, 2027$1,549,462 - $1,549,462
Brilliant epitopes for improved cancer vaccines
openAug 31, 2026$405,599 - $405,599
Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy
openAug 31, 2027$992,425 - $992,425
A Pilot Study to Correlate 4-[18F]fluoro-1-naphthol PET/CT Imaging with Chronic Graft Versus Host Disease Manifestations
openAug 31, 2027$358,605 - $358,605
Targeting cancer metastasis by inhibiting curvature-induced kinase activation
openAug 31, 2030$1,033,055 - $1,033,055
Efficient Measurement and Characterization of Genetic Interactions in Cancer Cells
openAug 31, 2030$370,173 - $370,173
Glyco-MAP: a high-throughput multiplexed platform for Glycosylated Mucin Antibody Profiling with glycoengineered cell lines expressing well-defined homogeneous glycostructures
openAug 31, 2027$183,494 - $183,494
Defining a globally accessible and pragmatic predictive signature (GAPPS) for locally advanced cervical cancer
openJul 31, 2029$498,565 - $498,565
Rapid inter-procedural 3D scanning of fine-needle aspiration cytology slides with a parallelized microscope
openAug 31, 2026$306,872 - $306,872
Deciphering the role of cancer pain-associated neuronal activity in driving malignancies
openAug 31, 2030$513,127 - $513,127
Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer
openAug 31, 2028$770,168 - $770,168
Targeted Delivery of Tumor Antigen esaRNA to the Spleen for Cancer Immunotherapy
openAug 31, 2026$399,300 - $399,300
Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies
openAug 31, 2026$399,739 - $399,739
Maximizing GlyTR pan-cancer immunotherapy by enhancing target density
openAug 31, 2028$463,510 - $463,510
Africa HepatoPancreatoBiliary Cancer Consortium
openAug 31, 2028$60,000 - $60,000
Leveraging Omics and Electronic Health Records Data to study Colorectal Adenoma genetics and Drug Repurposing
openAug 31, 2029$4,174,595 - $4,174,595
Understanding and Exploiting Loss of Y in Cancer
openAug 31, 2032$930,500 - $930,500
Expanding access to perioperative and repurposed drug trials in melanoma and other solid tumors
openAug 31, 2030$83,925 - $83,925
Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal Cancer
openAug 31, 2029$2,864,671 - $2,864,671
Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
openAug 31, 2026$399,985 - $399,985
Patient Navigation for Improving Transition Success Among Multiply Disadvantaged Young Adult Survivors of Childhood Cancer
openAug 31, 2029$4,236,812 - $4,236,812
Determining immune-mediated mechanisms of beneficial bacteria in colon cancer
openAug 31, 2028$201,960 - $201,960
Promoting Lead Academic Participating Sites (LAPS) Studies Accrual and Lung cancer Screening in Oklahoma
openAug 31, 2029$424,480 - $424,480
Evaluating Antigen Spread After cDC1 Vaccination
openSep 9, 2028$37,598 - $37,598
NeuroAccess: a Focused Ultrasound System for SonoBiopsy of the Brain
openAug 31, 2027$999,125 - $999,125
Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells
openAug 31, 2030$530,106 - $530,106
SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy
openAug 31, 2027$1,031,566 - $1,031,566
Unraveling the Impact of Extracellular Vesicle-Loaded FXR1 mRNA on Re-educating Cancer Microenvironment
openAug 31, 2030$494,160 - $494,160
Evaluating the adoption, implementation, and maintenance of a cervical precancer treatment in El Salvador
openAug 31, 2027$183,835 - $183,835
Feasibility of cue-based treatment intervention to promote cessation among people who smoke lightly (<=10 cigarettes per day) or non-daily
openAug 31, 2028$906,306 - $906,306
Scanner Agnostic Image-Guided Biopsy Platform Employing Advanced Computer Vision and Computer Graphics to Enable Non-Invasive Registration and Dynamic Projection Mapping
openAug 31, 2027$1,107,943 - $1,107,943
Trainee Symposium for IDeA state trainees
openAug 31, 2026$50,000 - $50,000
Focal Adhesion Kinase inhibition for dual targeting of osteosarcoma cells and the tumor microenvironment to prevent metastasis
openAug 31, 2030$629,341 - $629,341
Catalyzing cancer research through the use of advanced functional genomics and cell engineering technologies
openAug 31, 2029$491,315 - $491,315
Elucidating pathways underlying the association of contraception use with ovarian cancers through metabolic profiling
openAug 31, 2026$155,605 - $155,605
HLA LOH Detection via Liquid Biopsy: A Blood-Based Predictive Biomarker Assay for Precision Immuno-Oncology
openAug 31, 2026$406,500 - $406,500
Development of high parameter spatial transcriptomics and proteomics for the study of tumor microenvironments
openAug 31, 2029$584,510 - $584,510
Spatiomolecular Profiling of Human Cancer at Scale
openAug 31, 2028$372,628 - $372,628
Accurate Detection of Early-Stage Pancreatic Tumors using Artificial Intelligence Analysis of Abdominal Computed Tomography Scans
openAug 31, 2029$523,670 - $523,670
Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
openAug 31, 2030$817,829 - $817,829
Expanding Lung Cancer Screening to Achieve Excellence (EXHALE)
openAug 31, 2027$1,684,165 - $1,684,165
Differential activation of the triacylglycerol pathway in lipofibroblasts induces neurogenesis associated with prostate cancer progression
openJul 31, 2029$1,575,170 - $1,575,170
Inhibitors of ENPP1 for the treatment of hepatocellular carcinoma
openAug 31, 2026$306,739 - $306,739
DNA, RNA, and Chromatin Epigenetics: Disease and Development
openAug 31, 2026$10,000 - $10,000
Remotely-Delivered Cognitive Behavioral Stress Management Effects on Cancer-Accelerated Aging in Older, Distressed Breast Cancer Survivors
openAug 31, 2029$2,746,080 - $2,746,080
Genomic correlates of outcome in pleuropulmonary blastoma
openAug 31, 2030$528,902 - $528,902
Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia
openAug 31, 2026$409,732 - $409,732
Efforts to Discover Novel Therapies and Reduce Treatment Toxicities for Lymphoma and Chronic Lymphocytic Leukemia Patients Through Collaboration and the NCTN
openAug 31, 2029$935,075 - $935,075
Development of a novel MYC inhibitor for cancer therapy
openAug 31, 2027$1,102,729 - $1,102,729
Logic Gated Precision Molecular Adaptor System for Juvenile Myelomonocytic Leukemia Treatment
openSep 11, 2026$499,990 - $499,990
DEVELOP, QUALIFY IMMUNOLOGICAL ASSAYS, AND PROVIDE CLINICAL SAMPLE TESTING FOR AAV-BASED GENE THERAPY CLINICAL CANDIDATES
openSep 14, 2030$2,510,508 - $2,510,508
PRODUCING USHER III RETINAL ORGANOIDS FROM PATIENT CELLS TO MEASURE THE EFFECT OF DRUG CANDIDATE
openMar 15, 2028$794,843 - $794,843
EVALUATION OF IVO COMPOUNDS IN BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL
openSep 14, 2027$219,752 - $219,752
SBIR FY25 Concept Award: Development of engineered tRNA therapeutics for Clear Cell Renal Cell Carcinoma
openSep 14, 2026$355,000 - $355,000
TUMOR-DERIVED EXTRACELLULAR VESICLES FOR DIAGNOSIS OF EARLY-STAGE OVARIAN CANCER
openSep 14, 2026$354,828 - $354,828
A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma
openAug 31, 2026$400,000 - $400,000
MANUFACTURING PROCESS DEVELOPMENT OF 4-HB
openSep 14, 2030$917,706 - $917,706
NOMOCAN PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTPHASE I - DEVELOPMENT OF THERAPEUTIC OR PRE
openSep 14, 2026$499,166 - $499,166
SBIR FY25 CONCEPT AWARD: TARGETING DYSFUNCTIONAL CHROMATIN NETWORKS IN DIPG
openSep 14, 2026$355,000 - $355,000
STABILITY STUDY SUPPORT OF R-VK4-116
openMar 31, 2028$98,473 - $98,473
LEAD OPTIMIZATION OF A LONG NON-CODING RNA (LNCRNA) AS A POTENTIAL LIPID- AND GLUCOSE-LOWERING THERAPEUTIC
openSep 14, 2030$921,875 - $921,875
Modeling Enhancer Hijacking in Cancer via Genome Engineering and Single-Cell Sequencing
openAug 31, 2028$194,914 - $194,914
Assessing the impact of the substantial equivalence mechanism on the cigarette and cigar markets
openAug 31, 2030$816,307 - $816,307
Increasing Lung cancer screening Effectiveness and Access through Regional Networks (I-LEARN)
openAug 31, 2027$1,593,217 - $1,593,217
Minimally invasive pancreatic cancer treatment combining nanosecond electric pulses and immune system stimulants
openAug 31, 2026$303,475 - $303,475
NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE
openSep 14, 2027$2,977,013 - $2,977,013
INTERNAL AND EXTERNAL COMMUNICATIONS AND DISSEMINATION SUPPORT FOR DCCPS
openSep 14, 2026$50,000 - $50,000
CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) DEVELOPMENT OF NES-100 AS A NASAL SPRAY OF A NEW ANALGESIC
openSep 14, 2030$1,346,384 - $1,346,384
COORDINATED FACILITIES REQUIREMENTS FOR FY25 - FACILITIES TO I
openSep 13, 2030$15,054,787 - $15,054,787
Next Generation Dual Targeting ADCs for SCLC Empowered by Generative AI.
openSep 14, 2026$355,000 - $355,000
MANUFACTURING CGMP GRADE HYDROXYCOBALAMINE
openSep 14, 2026$61,516 - $61,516
NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC
openSep 14, 2026$354,456 - $354,456
A TBXT Inhibitor for Chordoma Therapy
openSep 14, 2026$354,991 - $354,991
Clinical evaluation of a novel AKT/PDK1 inhibitor, PHT-427, for the treatment of multi-field actinitc keratoses
openAug 31, 2026$2,085,765 - $2,085,765
Novel Thermoelectric Scalp Cooling System for Mitigating Chemotherapy-Induced Alopecia
openAug 31, 2026$305,040 - $305,040
Targeting Glycerol Metabolism in anti-Tumor Immunity
openAug 31, 2028$185,760 - $185,760
First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients
openAug 31, 2027$1,233,852 - $1,233,852
A COMPACT SOURCE FOR NEUTRON CAPTURE THERAPY FOR PONTINE GLIOMA.
openSep 14, 2026$500,000 - $500,000
Ultra-fast manufactured CAR-T therapy
openAug 31, 2027$1,125,000 - $1,125,000
Dissecting the Structure of Oligomeric BAK and the Implications for Reactivating Apoptosis in Cancer
openSep 14, 2027$75,520 - $75,520
Development of a novel liver-specific positron emission tomography tracer
openAug 31, 2026$400,000 - $400,000
Advancing Oncologic Research Communities in Health Equity (ARCH) K12 Program
openAug 31, 2030$54,000 - $54,000
Somatic Truncation Mutations of the Histone Methyltransferase MLL4 Alter Its Subcellular Localization in Bladder Cancer: Mechanistic Insight and Targeted Therapeutic Approach
openAug 31, 2029$2,970,010 - $2,970,010
Targeting STAT3 with Novel Thiomorpholino Antisense Oligonucleotides for Cancer Therapy
openAug 31, 2026$400,000 - $400,000
PHASE I FAST TRACK TOPIC 461 CONFORMABLE SCINTILLATOR ARRAY FOR IN VIVO DOSIMETRY DURING RT
openSep 15, 2027$1,977,698 - $1,977,698
Characterization of tumor-specific human endogenous retroviruses in clear cell Renal Cell Carcinoma
openSep 15, 2028$46,368 - $46,368
Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agent
openAug 31, 2026$306,265 - $306,265
Advancing Cancer Screening and Prevention Trials at the University of Colorado Cancer Center
openAug 31, 2029$547,080 - $547,080
CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
openAug 31, 2027$1,379,442 - $1,379,442
Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation
openAug 31, 2027$1,770,000 - $1,770,000
Expanded Safety and Preliminary Efficacy of Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women with HIV in Africa
openAug 31, 2030$34,064 - $34,064
Enhancing Solid Tumor lmmunotherapy with Targeted siRNA Delivery
openAug 31, 2026$406,500 - $406,500
SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma
openAug 31, 2027$1,146,618 - $1,146,618
Novel Biocompatible, High-Throughput Cryopreservation Medium and Method for Enhanced Post-Thaw Migration and Cytotoxicity of NK Cells
openAug 31, 2028$292,963 - $292,963
Correlating Genotype and Phenotype of Metastatic Cancer Cells In Vivo Using Nanolaser Optical Barcode
openAug 31, 2030$195,240 - $195,240
ACTIVATE: AI-driven Clinical Trial Information and Viability Assessment Tool for EHRs
openJun 30, 2030$833,467 - $833,467
FY2025 SBIR CONCEPT CLEARANCE AWARD FOR TOPIC DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS.
openSep 16, 2026$352,621 - $352,621
FY25 TO-B
openSep 30, 2027$2,052,772 - $2,052,772
The development of humanized SEMA7A-antagonist mAbs for the therapeutic treatment of breast cancer
openAug 31, 2026$392,695 - $392,695
Providing GMP-grade Terbium-161 as a therapeutic option for US academic institution
openAug 31, 2027$994,810 - $994,810
Design and optimization of TCR-T therapeutics by an advanced T cell receptor-antigen binding prediction platform
openAug 31, 2026$360,442 - $360,442
Point-of-care autologous CAR-T cell manufacturing
openAug 31, 2026$400,000 - $400,000
Validation of the Diagnostic and Predictive Tool, D2HGlo, for the Quantification of the Oncometabolite D-2-Hydroxyglutarate (D-2-HG) in Glioma
openAug 31, 2027$194,787 - $194,787
Cystoscopy-augmenting tools to improve the sensitivity and specificity of detection of urothelial carcinoma in situ
openAug 31, 2029$2,958,465 - $2,958,465
Novel wearable rotating magnetic field therapy device targeting treatment of brain cancers
openAug 31, 2027$1,296,385 - $1,296,385
A biodegradable barrier preventing anastomotic leaks after esophagectomy
openAug 31, 2027$406,500 - $406,500
Development of Localized Triple-Negative Breast Cancer Immunotherapy
openAug 31, 2026$398,039 - $398,039
Targeted Localization and Optimized Surgical Resection for Lung Cancer
openFeb 28, 2027$225,229 - $225,229
The AYA Oncology Self-Care Movement (#AYAOSM): An Influencer-Driven Social Media Intervention for Oral Chemotherapy Adherence
openAug 31, 2030$651,859 - $651,859
Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic
openAug 31, 2029$1,847,485 - $1,847,485
Together stronger: A family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers
openAug 31, 2030$680,600 - $680,600
Empowering cancer detection and monitoring with CampEx - CRISPR-accelerated molecular profiling of Extracellular vesicles
openAug 31, 2029$2,855,619 - $2,855,619
Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis
openAug 31, 2026$399,981 - $399,981
A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1)
openAug 31, 2027$1,197,275 - $1,197,275
Comprehensive Characterization of the T-cell Response to KSHV to Enable Specific Immune Therapy
openAug 31, 2029$4,234,248 - $4,234,248
Advanced Imaging Methods in Pulse EPR
openAug 31, 2027$1,164,814 - $1,164,814
Targeting the Unfolded Protein Response Master Regulator BiP to Induce CellDeath in Multiple Myeloma
openAug 31, 2030$280,638 - $280,638
A methyl arginine targeting chimera for the lysosomal degradation of intracellular proteins
openSep 19, 2027$46,539 - $46,539
SBIR FY25 Concept Award, Development of an Immunotherapy for Ewing Sarcoma Using a Novel Murine Model
openSep 21, 2026$355,000 - $355,000
Investigating the Role of VISTA in Driving Immune Evasion in Acute Myeloid Leukemia
openJun 30, 2030$654,837 - $654,837
The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes
openAug 31, 2026$314,685 - $314,685
Utilization of a novel dissimilarity approach to identify a novel mechanism of Merkel cell polyomavirus small tumor antigen nuclear import responsible for the development of Merkel cell carcinoma
openAug 31, 2028$547,875 - $547,875
Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer
openAug 31, 2027$285,599 - $285,599
Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic
openAug 31, 2027$919,366 - $919,366
Drug development of RK-33 for breast cancer treatment
openAug 31, 2027$1,634,811 - $1,634,811
MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE
openSep 21, 2027$3,460,074 - $3,460,074
Integrating genome-wide association study data with single-cell `omics' to reveal the cellular effectors of glioblastoma predisposition
openAug 31, 2029$1,882,680 - $1,882,680
Interoceptive, Affective, and Cognitive Control Networks that Determine Self-Regulation and Reinforcement Learning of Smoking Decisions
openAug 31, 2029$2,524,071 - $2,524,071
A Novel Benefits Navigator Intervention to Address Unmet Social Needs in Pediatric Oncology
openAug 31, 2030$249,647 - $249,647
Healthcare utilization and outcomes across the cancer care continuum: Understanding the impact of social risk factors and screening among Latino patients
openAug 31, 2030$649,293 - $649,293
CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy
openAug 31, 2027$1,313,567 - $1,313,567
UT Southwestern Simmons Comprehensive Cancer Center Clinical Oncology Research Career Development Award
openAug 31, 2030$54,000 - $54,000
Trends and outcomes of lung cancer screening among people with and without HIV in the US
openAug 31, 2029$2,991,283 - $2,991,283
A Delphi Study of Implementation Strategies for Cervical Cancer Control Policies in Africa
openAug 31, 2027$442,750 - $442,750
Increasing Global AMPERE (Access for Medical Physicists to Education and Research Excellence)
openAug 31, 2030$299,024 - $299,024
Androgen receptor signaling and sex differences in anti-tumor dendritic cell function
openAug 31, 2029$2,265,578 - $2,265,578
Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer
openAug 31, 2027$1,233,778 - $1,233,778
In chronic myeloid leukemia, persistence of leukemia stem cells during tyrosine kinase inhibitor treatment is influenced by interaction with αβT cells
openJul 31, 2030$477,218 - $477,218
Liquid Immunotherapeutic Fiducial Eluter (LIFE) Gel for Cervical Cancer
openAug 31, 2027$998,781 - $998,781
Determine genotypic, phenotypic and evolutionary trajectories of treatment resistance to radiotherapy.
openAug 31, 2029$2,105,127 - $2,105,127
FY25 TO-H W3F1 RENOVATIONS
openMay 18, 2027$1,856,809 - $1,856,809
Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancer
openAug 31, 2026$353,009 - $353,009
Development of a Virtual Preclinical CT Platform for Advanced Imaging and Theranostics in Head and Neck Cancer Research
openAug 31, 2029$2,896,024 - $2,896,024
Racial disparities in breast cancer risk and gene expression-roles of genetics and lifestyle factors
openAug 31, 2027$11,137 - $11,137
Comprehensive Liquid Biomarkers to Personalize Therapy in Renal Cell Carcinoma
openAug 31, 2029$2,984,495 - $2,984,495
Mechanisms and Impact of NRG3 Induction in Bone Metastasis
openAug 31, 2029$2,691,173 - $2,691,173
Natural killer cells subvert immune checkpoint therapy of tumors
openAug 31, 2029$3,182,665 - $3,182,665
Evaluating the Impact of Accessible and Scalable Digital Interventions to Address Co-Occurring Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design
openAug 31, 2029$3,355,681 - $3,355,681
Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC)
openMar 24, 2027$691,578 - $691,578
CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry
openAug 31, 2027$1,094,189 - $1,094,189
BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERSTASK ORDER TITLE: FURTHER DEVELOPMENT OF MITOCHONDRIA-TARGETED HONOKIOL
openMar 24, 2028$1,234,179 - $1,234,179
SBIR FY25 CONCEPT AWARD, TARGETING PLOD2 IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
openSep 28, 2026$354,878 - $354,878
PROVIDE A VARIETY OF CRITICAL CANCER PREVENTION INFORMATION MANAGEMENT FUNCTIONS
openSep 29, 2026$633,282 - $633,282
FY25 TO-C REFURBISH ELEVATORS
openSep 27, 2030$4,287,020 - $4,287,020
Understanding Treg-mediated modulation of microglia in breast cancer brain metastasis
openSep 29, 2029$46,540 - $46,540
REGULATORY SERVICES AND TECHNICAL SUPPORT TO THE DIVISION OF CANCER PREVENTION (DCP)
openSep 29, 2026$3,137,161 - $3,137,161
Quantitative CEST MRI for GBM Early Response Prediction and Biopsy Guidance
openNov 30, 2027$350,599 - $350,599
MERIT Extension of Optimization of a remote intervention to improve nutrition and physical activity in cancer survivors
openNov 30, 2027$691,400 - $691,400
SMARCA5 Inhibition as a Therapeutic Target for Glioblastoma
openNov 30, 2027$41,876 - $41,876
Immunomodulatory impact of the gut microbiome on tumor progression
openNov 30, 2029$33,538 - $33,538
Relative and synergistic contributions of PD1 and LAG3 on CD4+ T conventional cells in cancer
openNov 30, 2027$75,520 - $75,520
129Xe Hyperpolarized Chemical Exchange Saturation Transfer (HyperCEST) MRI for Tracking Immunotherapy Delivery in the Lungs
openDec 31, 2027$37,613 - $37,613
Epstein-Barr Virus positive post-transplant lymphoproliferative disorders: identifying viral and host variables to predict risk and develop novel management strategies
openNov 30, 2028$43,887 - $43,887
Defining the direct impact of m6A deposition on messenger RNA
openDec 31, 2028$75,520 - $75,520
Developing novel ALK targeting therapies through the expansion of targeted protein degradation
openDec 31, 2028$78,040 - $78,040
Nicotine promotes perineural brain metastasis by activating GABAergic neurons
openDec 31, 2028$248,984 - $248,984
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma
openDec 31, 2027$407,412 - $407,412
RNA's Role in Double-Strand Break Repair
openJan 6, 2029$49,538 - $49,538
Mechanisms of the small nucleolar RNA Snord67 in breast cancer lymphatic metastasis
openJan 17, 2027$87,964 - $87,964
Targeting vulnerabilities of PPM1D-mutant gliomas
openJan 31, 2028$404,055 - $404,055
Mitochondrial lateral transfer during metastasis
openJan 31, 2028$352,275 - $352,275
RISE UP for Breast Cancer 2026
openJan 31, 2027$12,500 - $12,500
Phase Transitions in Cellular Signaling and Disease
openJan 31, 2027$5,000 - $5,000
2026 DNA Damage, Mutation and Cancer Gordon Research Conference and Gordon Research Seminar
openJan 31, 2027$8,000 - $8,000
Engrailed-1 and Epigenetic Vulnerabilities in Metastatic Pancreatic Cancer
openFeb 28, 2028$357,267 - $357,267
A community-based trial of a voluntary smoke-free home intervention in permanent supportive housing for formerly homeless adults
openFeb 29, 2028$679,869 - $679,869
Role of Sirt2 in T Cell Metabolism - Extension
openFeb 29, 2028$357,994 - $357,994
The Novel Role and Mechanism of RBM33 in Leukemogenesis
openFeb 29, 2028$473,946 - $473,946
2026 Single-Cell Cancer Biology Gordon Research Conference and Gordon Research Seminar
openFeb 28, 2027$10,000 - $10,000
RNA Modifications: Bridging Biological Function and Therapeutic Potential
openFeb 28, 2027$10,000 - $10,000
Core A: Administrative Core
openFeb 28, 2031$314,391 - $314,391
Cancer Immunotherapy: Basic Mechanisms Informing Clinical Applications & Combinations
openFeb 28, 2027$5,000 - $5,000
2026 Autophagy in Stress, Development and Disease Gordon Research Conference and Gordon Research Seminar
openFeb 28, 2027$4,000 - $4,000
Geriatric oncology assessment to link with support for older women taking adjuvant aromatase inhibitor therapy
openFeb 28, 2031$668,691 - $668,691
Novel Multi-targeted Strategies Targeting T-cell Lymphomas and their Microenvironment
openFeb 28, 2031$646,920 - $646,920
The enabler of tumor cell immortality in TERT promoter mutant cancers
openFeb 28, 2031$658,722 - $658,722
High-throughput tools to track the fate of prematurely terminated transcripts in cancer cells
openFeb 28, 2029$237,023 - $237,023
Novel Monoclonal Antibody Tools for Exploring the Altered Glycocalyx in Tumor Cells
openFeb 28, 2029$430,521 - $430,521
Immunosuppression mediated by regulatory CD8+ T cells in lung cancers
openFeb 29, 2028$408,829 - $408,829
Treatment of neuroinflammation for remediation of chemoradiation-induced dysphagia
openFeb 28, 2031$634,644 - $634,644
Transcriptional suppression of innate immunity by chimeric transcription factors
openFeb 28, 2031$617,486 - $617,486
Theranostic Approaches to Breast Cancer Using Image Guided Surgery and Adjuvant PTT
openFeb 28, 2030$630,108 - $630,108
Addressing Thyroid Cancer Overdiagnosis: AI-Driven Identification, Characterization, and Outcomes of Incidental Thyroid Nodules
openFeb 28, 2031$676,067 - $676,067
An exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers
openFeb 28, 2031$738,675 - $738,675
Mechanistic basis and therapeutic strategies for PPP2R1A mutation in gynecological cancer
openFeb 28, 2031$653,967 - $653,967
A multimodal liquid biopsy assay to quantify androgen receptor’s somatic alterations in metastatic castration-resistant prostate cancer.
openFeb 29, 2028$225,511 - $225,511
2026 Metals in Medicine Gordon Research Conference and Gordon Research Seminar
openJul 31, 2026$5,000 - $5,000
Clinical Trial Support for the Rutgers Cancer Institute and the RWJBarnabas Health System
openFeb 29, 2032$975,000 - $975,000
From Atoms to Organoids: Understanding the Conformational Landscape and Regulation of Small GTPases
openFeb 28, 2028$141,566 - $141,566
Dissecting the role of tumor suppressing microRNAs in angiosarcoma
openFeb 28, 2031$437,654 - $437,654
TIRR/53BP1 complex regulates mitotic fidelity and immune-mediated radiation response
openFeb 28, 2031$683,075 - $683,075
AYA Cohort to Enhance Survivorship in NYC (ACES-NYC)
openFeb 28, 2031$1,053,426 - $1,053,426
Calcium Nanoparticles to Enhance Immuno-Radiotherapy
openFeb 28, 2031$618,236 - $618,236
Threading the needle: Development of Novel MR Methods for Effective Control of an Emerging Lipophilic Tumor Therapy
openFeb 28, 2031$593,557 - $593,557
Funder Overview
Total Opportunities1000
Grants1000
Contracts0
Visit this funder's website
Start a free 7-day trial to view National Cancer Institute's website, track new opportunities, and get deadline alerts. Cancel anytime.
Start free trial